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Pandemic Vibrio parahaemolyticus: Defining Strains Using Molecular Typing and a 
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Carisa Renee Davis 
 
 
ABSTRACT 
Vibrio parahaemolyticus is a leading cause of seafood-borne illness with a newly 
emerged pandemic strain.  Previous studies compared the pandemic and non-pandemic 
strains to understand the evolution of the pandemic strain but no definitive explanation 
for its emergence has been discovered.  This study investigated the molecular 
characteristics of the pandemic strain and growth characteristics at different temperatures.  
The hypothesis tested was that pandemic strains of V. parahaemolyticus have 
modifications to their proteome that give a selective advantage over the other V. 
parahaemolyticus strains at temperatures normally encountered in the environment.  
Molecular typing techniques; automated ribotyping, pandemic specific PCR and 
multilocus sequence typing (MLST), were compared to determine the best method for 
pandemic strain determination.  MLST was the best method because it was the most 
informative and accurate.  Furthermore, nine Florida outbreak strains were identified as 
 ix
pandemic.  Using representatives of both strains, growth curves were produced at four 
temperatures.  The five pandemic strains had a significantly faster growth rate at 12°C 
than five non-pandemic strains.  Temperature specific proteomic comparisons were 
completed using liquid chromatography followed by tandem mass spectroscopy.  The 
proteome differences between these two groups at 12°C included three proteins (DnaA, 
DnaJ-related protein and DnaK-related protein) with functions related to cold stress.  
DnaA was expressed in the non-pandemic strain and not the pandemic strain, while the 
reverse was true for DnaJ-related and DnaK-related proteins.  Western blot analysis and 
LC-MS/MS analysis on additional strains did not support the initial LC-MS/MS results.  
Growth studies using expression recombinants were employed to investigate these 
proteins on growth at 12°C.  The overexpression of DnaA and DnaJ-related proteins did 
not significantly alter the growth rates compared to the control strain, but the 
overexpression recombinant strains DnaK-5 has a significantly slower growth rate than 
the control strain, the opposite direction as expected.  The pandemic strain grows faster at 
lower temperatures, but the reason has not been determined.  A theory is offered in which 
the pandemic growth advantage related to regulation of cold stress, leading to a shorter 
lag phase and faster growth rate after acclimation to the lower temperatures.  Further 
experiments to investigate this theory are discussed. 
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Introduction 
Vibrio parahaemolyticus 
Background and Importance 
Vibrio parahaemolyticus, a halophilic, Gram negative, straight or curved rod 
shaped bacterium that possesses two types of flagella, a single polar flagellum and 
peritrichous flagella, accounts for about half of all Vibrio associated illness and is a major 
cause of seafood based illness throughout the world.  This bacterium is found in marine 
and estuarine environments, is associated with large outbreaks and sporadic cases (41, 47, 
50, 80, 90, 106).  The Center for Disease Control and Prevention (CDC) estimates that 
the US has 4,500 incidents of V. parahaemolyticus illness a year, but only about 215 
culture confirmed cases with 30 hospitalizations and 1-2 deaths (12). 
An outbreak of gastroenteritis in Osaka, Japan in 1950 was the first documented 
outbreak associated with V. parahaemolyticus.  During this outbreak, 20 of the 272 
patients contracting the illness died and the outbreak was linked to shirasu, a semidried 
sardine (29).  Two types of bacteria were isolated; one was identified as Proteus 
morganii and the second was a novel bacterium.  Morphology and biochemical tests were 
used to classify this novel strain.  Although it was similar to the Vibrio genus in 
movement and the possession of a polar flagellum, it was called Pasturella 
parahaemolyticus based on morphological differences and its inability to react with V. 
cholerae antiserum (11, 29, 42, 50, 73, 126).  Another study on halophilic bacteria 
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concluded that Pasturella parahaemolyticus was Pseudomonas enteritis (107).  A third 
study suggested that halophilism was a more important trait and the new genus 
Oceanomanas was proposed to include the newly renamed O. parahaemolyticus (69).  
The morphological, cultural, and biochemical properties of 1072 strains of halophilic 
bacteria were examined and P. parahaemolyticus was placed into the Vibrio genus as V. 
parahaemolyticus (50, 98).  The species was divided into two subgroups (98), but a later 
study determined that subgroup 2 was a separate species, V. alginolyticus (97). 
Since its discovery in the 1950s, incidence of V. parahaemolyticus has occurred 
worldwide.  This bacterium has been found in samples of water, plankton, sediment, fish, 
and shellfish from Asia, Europe, North and South America, and Africa (47, 50, 80, 90, 
106).  Just as the bacterium is spreading, so are occurrences of the disease.  V. 
parahaemolyticus was isolated from environmental samples in the US in 1967 (6).  After 
its isolation, there were unconfirmed cased of V. parahaemolyticus gastrointestinal illness 
in which either the bacteria was isolated from the suspected food or the affected patient, 
but not both from the same incident (18).  The first confirmed US case of gastrointestinal 
illness caused by V. parahaemolyticus occurred in Maryland in 1971.  During this time, 
there were three separate outbreaks in which 425 people became ill after the consumption 
of improperly prepared crabs (18, 42, 90, 126).  Incidence of V. parahaemolyticus has 
been reported in almost every coastal state in the US, including Alaska, but it is more 
common in the Gulf states (50, 59). 
 In the temperate zone, incidences of V. parahaemolyticus in environmental 
samples and illness have a seasonal trend in which there are more in the warmer months 
(9, 19).  The enumeration of V. parahaemolyticus in water samples throughout the year 
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indicates that the bacterium is mostly absent from the water column when temperatures 
fall below 15°C, but that it is found in the sediment (3, 51, 111).  After the water 
temperatures rise, V. parahaemolyticus leaves the sediment and returns to the water 
column (51, 111).  Studies enumerating V. parahaemolyticus in oysters have shown the 
same seasonal results (25, 104).  A study investigating the association of V. 
parahaemolyticus with crustaceans found that they change from being with benthic and 
planktonic copepods during the summer to benthic amphipods during the spring and 
autumn (39).  Similar to environmental samples, V. parahaemolyticus associated diseases 
are more frequent during the warmer months compared to the colder months.  Figure 1 
demonstrates the seasonal trend of illness and was published in a study of the reported V. 
parahaemolyticus illness in the US from 1988 – 1997 (19). 
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Figure 1. Vibrio parahaemolyticus infections in the United States reported to the CDC by 
month 1988 – 1997 (19). 
 
Pathogenicity 
There are three forms of diseases caused by V. parahaemolyticus; gastroenteritis, 
wound infections, and primary septicemia.  Of these, the gastrointestinal illness is the 
most common with diarrhea, abdominal cramps, nausea, and vomiting resulting from the 
consumption of raw or undercooked seafood (47, 90).  About 2 x 105 to 3 x 107 
organisms are required to cause illness, but the use of antacids lowers this amount (9, 
114).   The onset of illness occurs between 4 - 96 hours after ingestion and can last for up 
to two weeks (5, 111).  V. parahaemolyticus associated gastroenteritis is self-limiting, 
meaning that the disease lasts for a specific time regardless of treatment.  Generally, 
patients with V. parahaemolyticus associated gastroenteritis are treated with hydration 
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and antibiotics are only used in protracted cases (34, 48).  Wounds can be infected by 
exposure to seawater containing V. parahaemolyticus, and V. parahaemolyticus has been 
isolated from eyes, ears, and extremities (11, 19, 59, 90, 111).  Primary septicemia occurs 
when V. parahaemolyticus is present in the blood without a corresponding wound 
infection.  This illness is characterized by fever or shock (19).   
The mechanism of V. parahaemolyticus pathogenesis has been intensively 
studied, but it is still not fully understood.  Bacterial pathogenesis involves infection, 
entrance into host, replication, disruption of defenses and damage to host through the use 
of adhesion, secretion of toxins and invasion (28).  V. parahaemolyticus can adhere to the 
epithelial cells through proteins in the flagella (38, 67), and it can invade the epithelial 
cells (111).  Not all strains of V. parahaemolyticus are pathogenic.  However, pathogenic 
strains may possess one or both of the virulence factors; thermostable direct hemolysin 
(TDH) and TDH-related hemolysin (TRH).  Studies on the biological activity of TDH 
have shown it to be hemolytic, cytotoxic, enterotoxic, cardiotoxic and lethal in mice (42, 
70).  Some virulent strains of V. parahaemolyticus are β-hemolytic on Wagatsuma blood 
agar, which is referred to as the Kanagawa phenomenon (68, 100).  It was determined 
that TDH was responsible for this hemolysis (70, 124, 125).  TDH is a pore former and 
leads to diarrhea due to its role in the change in ion flux in intestinal cells (126).  TRH 
shares 67% amino acid homology with TDH and similar characteristics of hemolysis, 
lethality, and enterotoxicity.  TRH also plays a role in the change of ion flux by inducing 
calcium ion activated chlorine channels (42, 126).  
V. parahaemolyticus associated gastroenteritis is inflammatory in nature but the 
immunological mechanism has not been fully investigated.  The two branches of the 
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immune system are innate and adaptive immunity.  Innate immunity is a non-specific 
mechanism involving bactericidal, inflammatory, and phagocytic responses.  Acquired 
immunity is an antigen specific response in which immunity can be obtained though 
active and passive processes (96, 109).  Qadri et al. (91) concluded that V. 
parahaemolyticus initiates both acquire and inflammatory responses, but it is unknown if 
this is a response to the O and K antigens or a response to TDH.  Inflammation occurres 
in the small and large intestines and levels of C-reactive protein, nitric oxide metabolites, 
tumor necrosis factor-α, interleukin-1β, lactoferrin, and macrophages are elevated during 
the disease (91).  It has been noted that individuals with certain pre-existing conditions 
such as liver disease, diabetes, and alcoholism are at greater risk of a more severe illness, 
but the underling reason is unknown (9, 91). 
The V. parahaemolyticus genome was sequenced and virulence genes were 
investigated.  Similar to other members of the Vibrio genus, V. parahaemolyticus has two 
chromosomes (3.3 mb and 1.9 mb) that house 4832 genes (62, 106, 123).  Both 
chromosomes possess genes that are required for growth and viability, and genes for 
adhesion and toxin homologues were also located throughout the genome (62).   
A comparison of pathogenicity genes between the V. parahaemolyticus and V. 
cholerae genomes was completed, and V. parahaemolyticus was found to have genes for 
a type III secretion system (TTSS) located on both chromosomes that are absent in V. 
cholerae.  This finding suggests that V. parahaemolyticus has a different mechanism of 
pathogenesis than V. cholerae and explains the difference in disease caused by the two 
bacteria since TTSSs are involved in inflammatory diarrhea, a symptom associated with 
V. parahaemolyticus and not V. cholerae (9, 62).  Bacteria use TTSS to inject or secrete 
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proteins into host cells.  While the genes that encode the secretion system are conserved 
among different species, the secreted proteins differ (44).   The two sets of TTSS genes 
(TTSS1 and TTSS2) are functional; TTSS1 is involved in cytotoxicity while TTSS2 is 
involved in entertoxicity.  TTSS2 is found only in clinical strains while TTSS1 was found 
in both pathogenic and nonpathogenic strains (87).  Furthermore, a protein expressed by 
TTSS1 is involved in the cytotoxicity of V. parahaemolyticus to HeLa cells (84).   
A V. parahaemolyticus pathogenicity island (Vp-PAI) was discovered in the V. 
parahaemolyticus genome (46, 62, 105).  A pathogenicity island is a mobile genetic 
element important to the virulence of pathogenic bacteria (101).  The V. 
parahaemolytcius pathogenicity island is 80-kb and consists of the TTSS2 and tdh genes.  
The Vp-PAI was detected only in strains positive for the Kanagawa phenomenon 
suggesting its importance in virulence to humans (46).  
 
Identification and Detection 
Bacteriological culture methods are the gold standard for the isolation and 
identification of bacteria.  The US Food and Drug Administration (FDA) details the 
methodologies in the Bacteriological Analytical Manual (BAM) for the culture and 
isolation of V. parahaemolyticus from food samples.  The first step is isolation from the 
food sample through selective enrichment in alkaline peptone water followed by growth 
on thiosulfate citrate bile sucrose (TCBS) agar.  V. parahaemolyticus colonies are green 
on TCBS agar, which can be used to differentiate it from most Vibrios.  After the 
isolation of a pure culture from food, the next step is identification of the bacteria through 
biochemical testing (see Table 1), Grams staining and morphologic examination (27).   
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Table 1. Biochemical characteristics of V. parahaemolyticus.  Modified from (27) 
Test Result 
TCBS agar  Green colonies 
Arginine dihydrolase Negative 
Oxidase  Positive 
Ornithine decarboxylase Positive 
Lysine decarboxylase Positive 
Growth in NaCl No growth at 0% and 10%, growth at 3%, 6% and 8% 
Growth at 42°C Growth 
Sucrose Negative 
D-Cellobiose Variable 
Lactose Negative 
Arabinose Positive 
D-Mannose Positive 
D-Mannitol Positive 
ONPG Negative 
Acid  from 
fermentation 
of:  
Voges-
Proskauer 
Negative 
Vibriostatic 
agent O/129 
Resistant to 10 µg and susceptible to 150 µg 
Gelatinase Positive 
Sensitivity 
to:  
Urease Variable 
 
After isolation and identification of V. parahaemolyticus, serotyping is used to 
classify the bacterium by antigens on the outer membrane allowing investigators to group 
the bacterium from an outbreak.  The two antigens used to serotype V. parahaemolyticus 
strains are somatic O antigen and the capsular polysaccharide K antigen (50, 99, 107, 
111, 126).  The K antigen is heat-labile and is released by boiling for 1-2 hours in order 
to access the heat-stable O antigen (99, 111).  Some strains of V. parahaemolyticus are 
untypeable and some react with multiple antisera (112).  There is no correlation between 
pathogenesis and serotype, therefore serotype is more useful in outbreak investigations 
(4, 11). 
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Molecular methods have been used as rapid means for the detection of V. 
parahaemolyticus (23).  PCR assays, both standard and real time, have been developed 
for V. parahaemolyticus virulence factors tdh and trh (7, 8, 10, 22, 72, 81).  The tdh gene 
has been found mostly in clinical strains; only 1-2% of environmental strains carry this 
gene (75).  The thermolabile hemolysin gene (tlh) is species specific and has been used 
for the detection of all V. parahaemolyticus strains (7, 22, 108).  The use of these three 
targets allows for the detection of pathogenic and non-pathogenic V. parahaemolyticus in 
a variety of samples such as food, water and pure culture (7, 8, 10, 22, 72, 81).  V. 
parahaemolyticus enters into the viable but nonculturable (VBNC) state after prolonged 
exposure to environmental stress.   While in this state, the bacterium can cause disease 
but does not grow in culture media (83).  Because V. parahaemolyticus can enter into the 
VBNC state, the use of PCR as a method of detection is a valuable tool for investigators. 
 
Pandemic Strain 
Before 1995, the serotypes responsible for illness were varied.  A pandemic strain 
of V. parahaemolyticus with the serotype O3:K6 emerged in Asia around this time to 
become a predominate serotype causing illness.  A pandemic strain is defined as a strain 
that affects a large population in a wide geographical distribution (73).  It was first 
isolated from a patient who recently traveled from Indonesia to Japan.  The O3:K6 
serovar was also determined to be responsible for an outbreak in Taiwan in October 1995 
(73, 104).  During surveillance of patients with diarrhea in Calcutta, India in February 
1996, the O3:K6 serovar was found to be the most common cause of V. parahaemolyticus 
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illness (79).  This serovar was the first to have the ability to increase hospitalizations and 
replace existing serotypes in a given area (73). 
Since its discovery in Asia, the O3:K6 serovar has displayed a pandemic spread 
across the world.  The first US outbreak associated with the pandemic strain occurred in 
1998 causing 418 people to become ill in a multistate incident traced to oysters from 
Texas (20).  The pandemic strain has caused outbreaks in other states in the US, 
including Florida (23).  In addition to its prominence in Asia and North America, 
outbreaks associated with this serovar have been reported in South America (35, 57), 
Europe (64, 93) and Africa (1).   
Research on the pandemic strain has shown that members of the strain are highly 
similar even though the strain is undergoing changes.  The serotypes associated with the 
pandemic strain have diverged from only O3:K6 to 21 different serotypes including 
O4:K68, O6:K18, O1:K25, O1:K41, O5:Kuk and O1:Kuk (73).  The pandemic strain 
posses the tdh gene but not the trh gene (56, 73, 119, 127).  The search for a genetic 
marker for PCR that specifically identifies the pandemic strains uncovered two promising 
candidates, ORF8 and toxRS/new, but further testing has shown that these markers are 
not found in all isolates of the pandemic strain and therefore are not reliable (8, 81, 85).  
Based on a unique band found using arbitrary primed PCR profiles of the pandemic 
strains, a group specific PCR assay was developed that is a better indicator of 
pandemnicity than ORF8 and toxRS/new since it was found in all isolates of the 
pandemic strain (82).  The genomes of a pandemic O3:K6 and non-pandemic O3:K6 
were compared using subtractive hybridization and a 16 kb sequence was found in the 
genome of the pandemic strain which contains 10 proposed genes of unknown function 
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(80).  These studies demonstrate the genetic differences between the strains and illustrate 
the potential use of genotyping in differentiating pandemic and non-pandemic strains.  
The pandemic strain does not cause a more severe illness compared to non-
pandemic strains but it is becoming the dominate strain in some areas (4). Yeung et al. 
(127) found that the pandemic strain has enhanced adherence and cytotoxicity, and 
proteomic fingerprinting found a histone-like DNA-binding protein in the pandemic 
strains had a 16 kb insert in the 3’ end of the gene.  It has been suggested that differences 
between pathogenic and non-pathogenic strains may be evident in the proteome rather 
than the genome (116). 
 
Prevention of Illness from Shellfish 
In order to lower the risk of harvesting shellfish with very high levels of V. 
parahaemolyticus contamination, the Guide for the Control of Molluscan Shellfish (78) 
outlines the procedure for monitoring V. parahaemolyticus in the environment and in 
shellfish.  These guidelines allow for the closure of growing beds that have pathogenic 
bacteria above the limit (78).  Previous guidelines stated that overall limit of V. 
parahaemolyticus was 10,000 cells per gram of seafood (104).  However, this limit was 
insufficient due to an outbreak in 1998 where oysters in the growing areas had far fewer 
than this limit (52).  The current guidelines take into account testing isolates for the tdh 
gene and lowered the limit to less than 5 tdh+ cell forming units (CFUs) per 0.1 gram of 
shellfish.  Guidelines for the storage and transportation of shellfish intended for raw 
consumption indicate how fast shellfish need to be brought down to 10°C depending on 
the outside temperature to slow the bacterium’s growth (78).      
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Bioterrorism and V. parahaemolyticus 
Food-borne pathogens have been used in previous bioterrorism attacks and these 
attacks are initially suspected to be outbreaks and not intentional (58).  A disgruntled 
laboratory worker intentionally contaminated pastries with Shigella dysenteriae type 2 
which were left in the break room.  Twelve workers became ill with dysenteric symptoms 
and bacteria isolated from the patients was linked to a laboratory strain (55).  In 1984, 
there was a large outbreak of Salmonella Typhimurium in The Dalles, Oregon caused by 
the intentional contamination of ready-to-eat foods at salad bars.  A total of 751 persons 
became ill in two groups from multiple restaurants during September and October of that 
year and it took a year to catch the guilty parties.  Initially, it was thought that the 
outbreak was caused by bad hygiene practices at the restaurants.  It was not until a 
confession from a local religious group, Bhagwan Shree Rajneesh that a further 
investigation found that they wanted to sway the voting in an upcoming election to their 
favor and planned to use the intentional contamination of the salad bars to keep voters 
home.  The contaminations in September and October were trial runs and no further 
attempts were made.  The group failed to change the election to their favor (110). 
Due to the use of other food-borne pathogens to intentionally contaminate food, it 
is not unexpected that V. parahaemolyticus would be used in such a manner.  The 
bacteria in the previously mentioned attacks were laboratory strains that were bought or 
stolen (55, 110).  The abundance of V. parahaemolyticus in the environment and the 
availability to purchase it commercially make it easy to access.  Since, V. 
parahaemolyticus infection is caused after ingestion or infiltration of a wound (47, 90) 
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and aerosolation would be ineffective.  Therefore, the intentional contamination of food 
or water for a localized event would be the most effective way of dispersal (58).  
Methods to detect V. parahaemolyticus not only benefit the food industry but also those 
responsible for detecting a possible bioterrorist attacks. 
 
Molecular Typing Methods 
Molecular typing methods aid in local and global epidemiological investigations.  
These methods rely on changes in the DNA sequences which can accumulate either 
rapidly or slowly depending on selective pressure.  In areas where the selective pressure 
against change is high, the rate of accumulation of these changes is slow, and vice versa.  
Multilocus sequence typing (MLST) can be used to track slow changes in DNA 
sequences and is amenable to global epidemiological studies.  This technique involves 
the sequencing of an approximate 450 base pair section of a number of housekeeping 
genes, generally seven genes.  Advantages to using MLST are that its data is reliable, 
scalable, and portable between laboratories (17, 26, 103, 113).   
Areas that accumulate changes more rapidly are better suited to analysis by 
restriction fragment patterns to track the evolutionary relationships.  This is accomplished 
by two methods: ribotyping, which analyzes the rRNA operon and pulsed-field gel 
electrophoresis (PFGE), based on analysis of the whole genome (26).  Both ribotyping 
and PGFE involve the extraction of genomic DNA, fragmentation with restriction 
enzyme and separation by agarose gel electrophoresis.  PFGE, the gold standard of typing 
methods, compares the differences in the genomic DNA bands while ribotyping uses 
Southern hybridization to probe for the ribosomal RNA operon (4). DuPont Qualicon has 
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developed an automated method for ribotyping that uses the RiboPrinter™.  After the cell 
lysis by the user, the machine digests and separated the DNA, transfers it to a membrane, 
performs the Southern blot, photographs the blot and searches a pattern library for 
matches (92). 
Molecular methods have been used in outbreak investigations and linking 
outbreak strains to the pandemic strain.  Automated ribotyping was used to link outbreaks 
in the US to the pandemic strain (30).  Some pandemic strains are missing the ORF8 
pandemic marker, and PFGE was used to identify these as pandemic strains (13).  
Furthermore, PFGE was able to differentiate clinical V. parahaemolyticus strains from 
environmental strains (120).  Recently, a study suggested using either NotI or SfiI in the 
V. parahaemolyticus PulseNet PFGE protocol, which standardize the method for global 
surveillance (115).   
The clonal relationship of the pandemic strain was illustrated using molecular 
methods.  PFGE  using NotI was found to be more discriminatory than automated 
ribotyping using EcoRI at identifying the clonality of pandemic strains (127).   However, 
ribotyping using BglI and PFGE demonstrated that a clonal relationship exists among the 
pandemic strains that evolved from a single progenitor O3:K6 isolate (4, 14, 81, 117-119, 
127).  This clonal relationship was further supported by MLST analysis (15, 36).   
Additional methods have been used to investigate the pandemic strain.  Arbitrarily 
primed (AP) PCR fingerprints have been used to identify strains as pandemic and 
demonstrated that the pandemic strains were a unique clone (65, 79).    Enterobacterial 
repetitive intergenic consensus (ERIC) PCR uses a primer targeting a conserved sequence 
in-between ribosomal genes found in the family Enterobacteriaceae.  ERIC-PCR has a 
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discriminatory power comparable to PFGE and it can identify pandemic strains in less 
time (53, 118).   Two additional PCR based typing methods, repetitive sequence PCR 
(REP-PCR) and RNA template-specific PCR (RS-PCR) that also use conserved 
ribosomal gene spacer sequences were also found to have discriminatory power similar to 
PFGE (118).  Marshall et al. (63) compared ERIC-PCR, ribotyping, restriction fragment 
length polymorphism (RFLP) of the polar flagellum fla locus and PFGE.  Their study 
differed from other studies because they suggested that combining ERIC-PCR and 
ribotyping was more discriminatory than PFGE (63).  Multilocus variable number of 
tandem repeats analysis (MLVA) uses differences in the lengths of variable number of 
tandem repeats for typing.  MLVA was found to be useful in typing pandemic strains 
(54). 
 
Cold Stress 
The cellular process that occurs in mesophilic bacteria after temperature decreases 
from optimal levels has been studied in Escherichia coli.  Their response to cold stress 
occurs in two stages, a transient shock and a continuous acclimation, which are denoted 
by the expression of specific proteins.  Cold shock proteins (CSP) are expressed during 
the shock response and cold acclimation proteins (CAP) are expressed during acclimation 
(34, 86)  Cold stress in E. coli starts after the temperature fell below 20°C (34).  A 
majority of the studies into cold stress have involved a fast decrease in temperature, but 
this can also occur in a slow decrease in temperature (43).   
After the lowering of temperature, the bacterial cell undergoes biochemical and 
physiological changes to allow for the survival in colder temperatures.  The cell growth 
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stops and resumes at a lower rate after a lag period.  During this lag period, nucleic acid 
synthesis stops and the fluidity of the cellular membrane increases due to fatty acid 
desaturation.  While most protein expression ceases, the expression of CSPs increases.  
After the bacteria acclimate to the temperature, the expression of CSPs decreases while 
the cell returns to expression of other proteins (32, 34, 86).  The regulation of this biased 
protein expression is posttranscriptional.  There are both cis- and trans- elements that aid 
in the translation of cold induced proteins.  The translational bias of cold stress proteins is 
also helped by initiation factor, especially IF3, which selects for cold stress mRNAs in 
low temperatures (31). 
CspA is a major protein in cold stress and it accounts for 13% of the expressed 
protein during this process in E. coli (33).  The mRNA of this protein is only stable at low 
temperatures due to the temperature controlled binding of a translation factor.  CspA 
binds to single stranded DNA and RNA, possibly acting as an RNA chaperone (48).     
The cold stress protein DnaA is involved in the initiation of DNA replication.  
The origin of replication, oriC, consists of 5 DnaA boxes in which DnaA binds.  In order 
for DNA unwinding to occur, approximately 20 DnaA-ATP molecules are needed (102).  
Expression of DnaA is two fold higher at lower temperatures than at 37°C, but the 
amount of DnaA need for initiation at oriC does not change (2).      
Table 2 lists the function of identified cold stress proteins.  There are proteins 
involved in DNA replication and repair such as RecA and NusA, as well as proteins 
involved in the physical changes to the DNA and cell, such as DNA gyrase alpha subunit, 
and the desaturase, DesA and DesB.  Numerous molecular chaperones have also been 
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identified as cold stress proteins.  These include DnaK, DnaJ, peptidylprolyl isomerase 
1A and HSC 66 (32, 34, 37, 43, 86, 121). 
Cold stress proteins in members of the Vibrio genus are homologous to those 
found in E. coli.  V. cholerae has slight differences due to its having two major cold stress 
proteins, CspAVC and CspV, instead of one (21), and homologues of these two proteins 
were identified in V. vulnificus (61).  
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Table 2. Cold stress proteins identified in E. coli and their functions (32, 34, 37, 43, 
86, 121) 
Protein Function 
CspA Major protein; control function 
DnaA Initiator at OriC 
CspB RNA binding 
CspG Unknown 
CshA RNA helicase 
CshB RNA helicase 
CsdA RNA unwinding 
DesK Histidine kinase 
DesR Transcriptional regulation 
DNA gyrase alpha subunit DNA supercoiling 
DnaJ Molecular chaperone 
DnaK Molecular chaperone 
Desaturase, DesA & DesB Desaturates fatty acids in membrane 
Dihydrolipoamide 
acetyltransferase, AceF 
Pyruvate dehydrogenase 
Elongation factor Tu Binding and transporting of aminoacyl-tRNA 
InfB Binding of charged tRNA-fmet to 30S ribosomal 
subunit 
InfA  Binding of charged tRNA-fmet to 30S ribosomal 
subunit 
HtpG Molecular chaperone 
H-NS DNA compaction 
Hsc66 Molecular chaperone 
gamma-glutamyltranspeptidase Glutathione metabolism 
NusA Termination of transcription 
Peroxidase/catalase HPI catalase and peroxidase 
Polynucleotide phosphorylase 
(PNP) 
Degradation of mRNA 
peptidylprolyl isomerase 1A Molecular chaperone 
Pyruvate dehydrogenase, AceE Decarboxylation of pyruvate 
RecA Recombination and repair 
RbfA Ribosomal maturation or initiation of translation 
Trigger Factor, TF Prolyl-isomerase activity and other functions 
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Objectives 
In 1995, a pandemic strain of Vibrio parahaemolyticus emerged, but how this 
occurred and what additional traits this strain possesses are not fully understood.  The 
definition of the pandemic strain includes clonality of the strains but there is no 
consensus as to a method for determining clonality.  This study intended to investigate 
the viability and proteomes of the pandemic and non-pandemic strains as they are grown 
at various temperatures in order to identify any pandemic specific differences.  The 
hypothesis tested was that pandemic strains of V. parahaemolyticus have modifications to 
their proteome that give a selective advantage over the other V. parahaemolyticus strains 
in temperatures normally encountered in the environment.  The following specific aims 
were used to test this hypothesis: 
 
1. To compare molecular methods used to identify pandemic and non-pandemic 
strains and determine a common molecular method. 
2. To compare the viability of these strains at different temperatures to determine if 
the pandemic strains have an advantage over the non-pandemic strains.   
3. To compare the proteomes of the pandemic and non-pandemic strains in growth 
conditions where the pandemic strains have an advantage.   
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Materials and Methods 
V. parahaemolyticus Strains 
 A total of 37 V. parahaemolyticus strains were used in this study (Appendix A).  
Food borne outbreak related V. parahaemolyticus strains were isolated and identified 
using the BAM (27), and these strains were serotyped using the V. parahaemolyticus O 
and K antisera (Denka Seiken, Co., LTD.; Tokyo, Japan). Strain C&RSF was isolated 
from mussels and EnvDOH-04-001 from oysters, each associated with a food borne 
outbreak.  MDOH-03-17267-Vp, MDOH-03-17282-Vp, MDOH-03-17294-Vp, MDOH-
03-17297-Vp, MDOH-03-17298-Vp, MDOH-03-17299-Vp, and MDOH-03-17301-Vp 
were isolated from patients linked to a food borne outbreak caused by both V. 
parahaemolyticus and V. cholerae.  MDOH-04-5M732 and MDOH-04-5M734 were 
isolated from patients associated with another food borne outbreak.  Additional V. 
parahaemolyticus strains, including pandemic strains, were acquired from American 
Type Culture Collection (Manassas, VA), the FDA Gulf Coast Seafood Laboratory and 
Dr. Valerie Harwood at the University of South Florida.   
 
DNA Extraction 
DNA was extracted from pure overnight bacterial cultures grown in 4 mL of 
trypic soy broth (TSB; Remel; Lenexa, KS) using the PrepMan® Ultra Sample 
Preparation Reagent (Applied Biosystems; Foster City, CA).  A 1 mL sample of culture 
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was centrifuged for 3 minutes in a microcentrifuge at maximum speed.  The supernatant 
was removed and the pellet was resuspended in 200 uL of the ABI Prepman reagent.  The 
sample was then boiled for 10 minutes at 100ºC.  Afterwards, the sample is spun in the 
microcentrifuge for 3 minutes at maximum speed.  The resulting supernatant is 
transferred to a fresh tube and used for PCR.   
 
Real Time PCR 
Primers and TaqMan® probes (Table 3) were designed for real time PCR assays 
to detect the reverse complement of the tdh, trh, and tlh genes using the ABI Primer 
Express® (version 1.7; Applied Biosystems; Foster City, CA) software.  Multiple 
GenBank sequences were used in the generation of primers and probes.  For the tdh gene, 
these sequences are Accession number D90238, S67841, X54342, S76724, X54343, 
X54341, X54340, and M10069 (74).  The GenBank accession numbers used for the trh 
gene are AB038238 and S67850, and for the tlh gene, the accession numbers are 
AY289609, M36437, and AB012596 (74).  A multiple sequence alignment was generated 
for each gene so sequence differences could be avoided during primer and probe design. 
All oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA).  
Real time PCR was carried out using the LightCycler® (Roche Diagnostics; Indianapolis, 
IN).  Each reaction was set up as following, the total reaction volume was 20 µL, which 
contained an 18 µL master mix containing 2 µL of Hybridization Mix, 3 mM MgCl2, 900 
nmoles of each primer, and 250 nmoles of probe for each sample.  The master mix was 
added to each capillary tube in the LightCycler Carousel and 2 µL of bacterial DNA.  The 
Carousel was spun briefly before being loaded into the LightCycler®.  The 
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thermocycling program started with a template denaturation step for 4 minutes at 95°C 
followed by the amplification profile of 40 cycles of 95°C for 15 seconds followed by 
60°C for 15 seconds.  After the program was completed, the LightCycler® Quantification 
Report based on the run was examined to determine if the samples were positive or 
negative for the gene.  A positive reaction is indicated by a crossing point value.  This 
value relates to the cycle in which the fluoresces increases over the background (95).   
 
Table 3. Fluorogenic primers and probe used for amplification of the tdh, trh, and tlh 
genes in V. parahaemolyticus 
Description Sequence
a 
tdh-Forward 5'-CATCTTCGTACGGTTTTCTTTTTACA-3' 
tdh-Reverse 5'-TCTGTCCCTTTTCCTGCCC-3' 
tdh-Probe 
5'-FAM-TCTCGAACAACAAACAATATCTCATCAGAACCG- 
BHQ1-3' 
trh-Forward 5’-GCCAAGTGTAACGTATTTGGATGA-3’ 
trh-Reverse 5’-TGCCCATTTCCGCTCTCA-3’ 
trh-Probe 5’-FAM-ACGCCAGAATATTTCGTCAATGTCGAAGC-BHQ1-3’ 
tlh-Forward 5’-CGAGAACGCAGACATTACGTTC-3’ 
tlh-Reverse 5’-TGCTCCAGATCGTGTGGTTG-3’ 
tlh-Probe 5’-FAM-TCGCCGCTGACAATCGCTTCTCAT-BHQ1-3’ 
a
 FAM, 6-carboxyfluorescein; BHQ1, Black Hole QuencherTM-1 
 
 
Pandemic Group Specific PCR 
 Seven different primer sets targeting pandemic specific markers have been published 
(Table 4).  PCR reactions were set up using 10mM Tris-HCl, 50mM KCl, 1.5 mM 
MgCl2, 0.2 mM of each dNTP, 12.5 pM of each primer, and 0.625 Units of Taq 
polymerase (Takara Bio; Shiga, Japan).  For the primers O3MM824, ORF8A/B, 
ORF8C/D and PGS, the PCR conditions started with a 3 minutes of denaturation at 94°C 
followed by 30 cycles of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 
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minute with a 5 minute final extension at 72°C.  The primer sets GS-V and F2-1 followed 
a similar protocol but the annealing temperatures were 45°C and 55°C, respectively.  
PCR conditions for VP36RF8 had an initial denaturation at 96°C for 5 minutes followed 
by 25 cycles of 94°C for 1 minute, 53°C for 1 minute and 72°C for 1 minute ending with 
a 7 minute final extension at 72°C.  PCR products were separated on a 1% agarose gel 
containing ethidium bromide, visualized with UV and documented using the GelDoc 
(Bio-Rad; Hercules, CA). 
 
Table 4. Pandemic Group Specific PCR target information. 
Target Name Reference 
O3MM824 Myers et al. 2003 (72) 
ORF8A/B Okura et al. 2003 (81) 
Iida et al. 2001 (45) 
ORF8C/D Okura et al. 2003 (81) 
ORF8 
VP36RF8 Laohaprertthisan et al. 2003 (56) 
toxRS/new GS-V Matsumoto et al. 2000 (65) 
Okura et al. 2003 (81) 
VP2905 (HU insertion sequence) F2-1 Okura et al. 2005 (80) 
Unknown (AP-PCR band) PGS Okura et al. 2004 (82) 
 
 
Automated Ribotyping 
The RiboPrinter (DuPont Qualicon; Wilmington, DE) was used to ribotype the 
strains according to the manufacturer’s protocol.  This protocol involved the heat 
treatment of the cells prior to loading them on to the machine.  The machine began by 
digesting the DNA into fragments via a restriction enzyme. These fragments were 
separated by size through gel electrophoresis and then transferred to a membrane, where 
they were hybridized with a DNA probe to the rRNA operon and mixed with a 
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chemiluminescent agent.  A digitizing camera captured the light emission as image data, 
from which the system extracted a riboprint pattern.  This pattern was compared to others 
in the database for characterization and identification (92).  The restriction enzyme PvuII 
was used in this technique.  The resulting RiboPrint patterns were imported into 
BioNumerics® (Applied Maths; Austin, TX) and Unweighted Pair Group Method with 
Arithmetic mean (UPGMA) dendrograms were generated based on similarity coefficients 
calculated using the Dice coefficient.  UPGMA is an algorithm that builds a tree by first 
grouping together the two taxa most closely related then sequentially adding in the more 
distantly related taxa (71).   
 
Multilocus Sequence Typing 
 MLST was performed in accordance with Chowdhury et al. (15) for loci gyrB, recA, 
dnaE, and gnd.  Due to amplification problems using previously published primers, new 
primers (Table 5) were designed that targeted the area of the gene containing the loci 
from Chowdhury et al. (15) plus flanking regions.  Using the previously published or the 
newly designed primers and PCR conditions cited for primers O3MM824, ORF8A/B. 
ORF8C/D and PGS, each of the four loci was amplified from 30 strains and sequenced.  
The resulting sequence was compared by BLAST search to determine if it matched a 
previously publish allele (15).  If the loci did not match 100% to a previously identified 
allele, then the new allele was numbered according to Chowdhury et al. (15).  Sequence 
types (STs) were assigned to complete allelic profiles based on their order in the table 
from Chowdhury et al. (15) and novel STs were numbered accordingly.  A dendrogram 
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based on STs was created using UPGMA with the Sequence Type Analysis and 
Recombinational Tests (START) program (49).   
 
Table 5. Additional MLST Primers published by Chowdhury et al. (15). 
Loci Product Size Primer Sequence 
recA-F 5'-GCTGCTGCACAACGTGAAGGTAAA-3’ recA 703 
recA-R 5'-TTCTGGATGCTCACGCAGGTAGTT-3’ 
dnaE-F 5'-ACATTAGAAGATCCACGCCGACCA-3’ dnaE 706 
dnaE-R 5'-ACGGTCAACGAAACCAAATGGGTG-3’ 
gyrB-F 5'-AGAACGTGAAGACGGTATCTCGGT-3’ gyrB 560 
gyrB-R 5'-AGTTTGTCCGGGTTGTACTCGTCA-3’ 
570 Gnd-F1 5'-GCGAAGAAGGTGCCCGTTTG-3’ 
Gnd-F2 5'-GAAGCGGTTAAGCCTATCTTCC-3’ 
gnd 
511 
Gnd-R 5'-CTTCTACTGGCGTGATGGTCTTAC-3’ 
 
 
Growth Curves 
In order to determine viability, growth curves were created for each temperature 
tested.  Four temperatures were chosen to mimic the average winter and summer 
temperatures in the Gulf of Mexico (77) and Kii Channel in Japan (40), two places V. 
parahaemolyticus are known to grow (Table 6).  Two strains (non-pandemic strain 
C&RSF and pandemic strain VP47/BAA-238) were initially used and 8 additional strains 
(non-pandemic strains ATCC 17802, 10292, AQ 4037 and NY 477; pandemic strains 
VP81/BAA-239, VP185/BAA-240, VP232/BAA-241 and VP250/BAA-242) were added 
for further testing.  A single colony from a tryptic soy agar (TSA) plate (Remel; Lenexa, 
KS) was transferred to 4 mL of TSB (Remel; Lenexa, KS) and grown overnight at room 
temperature for the summer temperatures (27.5°C and 30°C) or at the winter 
temperatures (12°C and 17°C) to be tested.  An overnight culture was used to inoculate 
100 mL of TSB (BD; Franklin Lakes, NJ) with 2.1% NaCl (Sigma; St. Louis, MO) until 
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the optical density at 600 nm (OD600) was between 0.01 and 0.03.  This culture was 
grown for 5 – 8 hours at the tested temperature and 1 mL samples were taken every 30 
minutes.   An indirect count of the bacteria in the sample was taken by OD using a 
spectrophotometer at 600 nm.   At every time point, viable counts were also performed.  
This was done by diluting the sample using 0.9% saline and plating the 10-5 to 10-9 final 
dilutions on TSA plates and incubating them overnight at 35°C.  Data from the OD 
readings and viable counts were plotted against time and a growth curve was created 
(16).  Each experimental condition was done in triplicate and the values at each time 
point was averaged.  Growth curves for the pandemic and non-pandemic strains were 
generated, and the mean generation times compared using SAS version 9.0 (SAS 
Institute; Cary, NC).  The data was first checked for normality by testing the 
homogeneity of variance, and it was found to be heterogeneous and the log of the data 
was used in further tests.  The data was tested using a two-way ANOVA using strain and 
temperature as factors.  If the strain X temperature interaction was significant, contrasts 
were done using a one-way ANOVA to determine which temperature had the significant 
difference between the two strains.  Since multiple contrasts were done, sequential 
Bonferroni was used to adjust the level of significance to eliminate false positives (94).  
If a significant difference was found at a temperature, additional strains were tested at 
that temperature. 
 
Table 6. Temperatures used during the Growth Curves and their corresponding 
geographical location (40, 77). 
Time Kii Channel, Japan Temperature Gulf of Mexico Temperature 
Winter 12ºC 17ºC 
Summer 27.5ºC  30ºC 
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Proteomic Analysis 
 Proteomic analysis was done using strains C&RSF and VP47/BAA-238 from the 
growth curve experiments.  Three separate cultures of each strain for both 12°C and 30°C 
were grown in 200 uL of TSB with 2.1% NaCl to an OD600 between 0.8 and 1.0.  The 
culture was transferred into 50 mL tubes and spun at maximum speed in a centrifuge for 
5 minutes.  The supernatant was decanted and the pellets were resuspended in 1 mL of 
sterile Nanopure water and combined into one 2 mL microfuge tube.  The samples were 
spun in a microcentrifuge at maximum speed for 3 minutes.  The supernatant was 
decanted and the pellet was held at -80°C until protein was extracted. 
Protein was extracted from the pellets in two fractions (soluble and insoluble) using 
the ReadyPrep Protein Extraction Kit (Bio-Rad; Hercules, CA).  The frozen pellets were 
removed from the -80°C freezer and 10 uL of Protease Inhibitor Cocktail (Sigma; St 
Louis, MO) was added while the pellets thawed.  To each thawed pellet, 1 mL of ice cold 
lysis buffer was added followed by 0.5 mL glass beads.  The sample was vortexed for 1 
minute and then cooled on ice for 1 minute.  The vortex and icing steps were repeated 
four times.  After the final icing, the bead settled to the bottom of tube.  The liquid was 
transferred to a fresh tube using pipette tips with very thin openings to ensure that no 
beads were transferred.  To get rid of any nucleic acids, 0.8 uL of the endonuclease 
Benzonase (Sigma; St Louis, MO) was added to each sample and the tubes were inverted 
five times.  The samples were then spun at 20,000 x g for 20 minutes.  The supernatant 
was transferred to a fresh tube on ice.  To the pellet, lysis buffer was added and it was 
vortexed to resuspend the pellet.  This was spun at 20,000 x g for 20 minutes.  The 
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supernatant was combined with previously collected supernatant and it was frozen at -
20°C.  To prepare the insoluble fraction, 0.5 mL of 2-D rehydration/sample buffer 1 was 
added to the pellet and it was vortexed until completely solubilized.  The sample was 
spun at 20,000 x g for 10 minutes.  The supernate was transferred to a fresh tube and 
frozen at -20°C.  To ensure that sample sent to the Proteomics Core Facility at H. Lee 
Moffitt Cancer Center and Research Institute did not contain live bacteria, a 5 minute 
exposure UV-C light was used to kill any remaining bacteria.  After exposure, twenty-
five percent of each protein sample was plated onto a TSA plate and incubated at 30°C 
for 72 hours as a confirmation that no live bacteria were present in the sample. 
Protein samples were quantitated using the 2-D Quant Kit (Amersham Biosciences; 
San Francisco, CA).  Using this kit, the protein quantification was estimated using a 
colorimetric agent to detect the amount of copper bound to protein in the sample.  The 
protocol utilizes a standard curve using bovine serum albumin (BSA).  In all samples, the 
protein was precipitated to eliminate any reagents used during protein extraction.  The 
precipitated protein was resuspended in a copper containing solution and a colorimetric 
solution.  The samples were incubated at room temperature for 15 – 20 minutes before 
their absorbance at 480 nm was read on a spectrophotometer.  The standard curve was 
generated by plotting the absorbance by the quantity of protein and the protein 
quantification of the samples was determined by fitting their absorbance to the standard 
curve. 
 Protein samples were sent to the Proteomic Core Facility for LC-MS/MS analysis.  
At the Proteomics Core Facility, the protein extracts were thermal denaturated at 95ºC for 
5 minutes followed by an overnight digestion with trypsin.  The peptides in the trypsin 
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digested protein extracts were separated using liquid chromatography and identified using 
tandem mass spectroscopy.  The Mascot program (Matrix Sciences; Boston, MA) 
searches a database of full length protein to match the peptide fragments identified of the 
MS/MS data.  It also calculates a probability score for these matches (60).  The Mascot 
search data were then imported into the Scaffold program (Proteome Software; Portland, 
OR) that validated the protein matches and compared that MS/MS data across sample 
groups.  The Scaffold file was used to indentify proteins of interest, or the proteins 
identified for further investigation by overexpression studies and western blot analysis. 
 
Overexpression Study 
 A functional study was used to determine if the addition of proteins identified in 
the proteomics analysis affected growth at 12°C.  These studies involved the use of 
expression vectors to study the pandemic or non-pandemic protein of interest in E. coli 
strains. 
 To make the expression vectors, the Flexi Vector kit (Promega; Madison, WI) 
was used.  The gene of interest was amplified using PCR (see Table 7 for primers 
sequences).  The PCR reactions were then purified using the Wizard SV Gel and PCR 
Clean-up System (Promega; Madison, WI).  The PCR reaction was transferred to an SV 
Minicolumn and incubated at room temperature for 1 minute.  The SV Minicolumn was 
then centrifuged at 16,000 x g for 1 minute and the flow through was discarded.  The 
column was washed with Membrane Wash Solution followed by centrifugation at 16,000 
x g for 1 minute.  After the flow through was discarded, more Membrane Wash solution 
was added and the column was centrifuged again for 5 minutes.  The resulting flow 
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through was discarded and the column was centrifuged for 1 minute with the lid open.  
The SV column was transferred to a clean 1.5 mL microcentrifuge tube.  Nuclease-free 
water was added to the column and it was incubated for 1 minute at room temperature.  
The column was centrifuged for 1 minute to elute the purified PCR product.   
 
Table 7. PCR primer sequences for expression vectors.  
Protein Primer Sequence 
dnaA F 5'-CTAAGCGATCGCCATGTCATCTTCGCTTTGGCTGCAAT-3' DnaA 
dnaA R 5'- CGGCGTTTAAACAGAAGACAGGGTGCGAATCAAG-3' 
dnaK-rel F 5'-GACCGCGATCGCCATGGCATCTCCTCGTTTTCT-3' DnaK-
related dnaK-rel R 5'- ATGGGTTTAAACATGATGAACAAGTGTTAAACCG-3' 
dnaJ-rel F 5'-ATATGCGATCGCCATGCATATTTTTGGCAAAATTC-3' DnaJ-
related dnaJ-rel R 5'- GTGCGTTTAAACCTTAAAGCCTTTTACCTTTTTAAT-3' 
 
 
 The next step involves restriction digestion of the Flexi vector and purified PCR 
product with the enzymes SgfI and PmeI.  Separate digestion reactions were set-up for the 
purified PCR product and vectors and they were digested with the enzymes for 30 
minutes at 37°C.  The Flexi vector reaction was then heated to 65°C for 20 minutes to 
inactivate the enzymes.  Membrane Binding Solution was added to the PCR product and 
the PCR product was purified using the previous protocol.  The PCR product and the 
Flexi vector were then ligated using T4 DNA Ligase and incubation for 1 hour at room 
temperature. 
 The ligation reaction was then transformed into competent E. coli cells.   This 
protocol began with the centrifugation of the ligation reaction and transfer of 2 uL of this 
reaction to a 1.5 mL microcentrifuge tube on ice.  JM109 competent E. coli cells were 
thawed on ice and 50 uL of the cells were added to each ligation reaction tube.  The tubes 
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were gently mixed and placed on ice for 20 minutes.  The cells were then heat-shocked at 
42°C for 45 – 60 seconds and then returned to ice for 2 minutes.  SOC medium was then 
added to the tubes, which were incubated in a shaking water bath set to 150 rpm and 
37°C for 1.5 hours.  The transformation reaction was then plated in duplicate on LB 
plates containing 25 ug/mL kanamycin and incubated overnight at 37°C.  Resulting 
clones were screened for the insert by restriction digestion of plasmid and real time PCR.  
A strain containing the insert was then used in growth curves at 12°C, as 
previously described, to determine if the presence of the protein affects the growth of the 
recombinant strains compared to JM109 strain.  SAS version 9.0 was used to test for 
significant differences in the growth curves using the mean generation.  The test for the 
homogeneity of variance indicated that the data were normal and t-tests were used to test 
for significant differences in the mean generation times between the strains. Since 
multiple t-tests were done, sequential Bonferroni was used to adjust the level of 
significance to eliminate false positives (94). 
 
Western Blotting 
 The same ten strains that were used in the growth study experiment were analyzed 
for the proteins of interest by western blot.  V. parahaemolyticus cultures for each strain 
were grown at 12°C and at 30°C in 100 uL of TSB with 2.1% NaCl until the OD600 was 
above 0.5.  The culture was transferred into 50 mL tubes and spun at maximum speed in 
a centrifuge for 5 minutes.  The supernatant was decanted and the pellets were 
resuspended in 1 mL of sterile Nanopure water and combined into one 2 mL microfuge 
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tube.  The samples were spun in a microcentrifuge at maximum speed for 3 minutes.  The 
supernate was decanted and the pellet was held at -80°C until protein was extracted.  
 In addition, the expression recombinants (DnaA-1, DnaJ-1 and DnaK-5) were 
used as positive controls and JM109 E. coli cells were used as negative controls.  
Cultures of recombinant E. coli cells were grown in 10 mL of Luria-Bertani (LB) broth 
(BD; Franklin Lakes, NJ) with 25 ug/mL kanamycin (Fisher Scientific; Pittsburgh, PA) at 
30°C until the OD600 was above 0.5, while the JM109 E. coli cells were grown in LB 
broth without kanamycin.  Protein was extracted from these cultures by boiling 1 mL of 
the cultures for 10 minutes. 
 Protein was extracted using the B-PER Bacterial protein Extraction Regent 
(Pierce Biotechnology; Rockford, IL).  The cell pellets were removed from the -80°C 
freezer and 10 uL of protease inhibitor cocktail was added to the pellet.  After the pellet 
thawed, 5 mL of B-PER reagent was added and the pellet was resuspended into a 15 mL 
conical tube.  The cell/B-PER mixture was then placed on the vortex and gently shaken 
for 10 minutes.  After the 10 minutes, 1.0 uL of Benzonase was added and the tube was 
inverted five times to mix.  In order to separate the protein, the mixture was centrifuged 
at 15,000 x g for 15 minutes.  Finally the supernatant containing the soluble fraction was 
transferred to a new 2 mL microfuge tube while the pellet (insoluble fraction) was 
resuspended in 5 mL of B-PER reagent.  Both fractions were held at -80°C until the 
protein extract was used in western blot.   
 The concentrations of the protein extracts were quantified using BCA Protein 
Assay Kit (Pierce Biotechnology; Rockford, IL).  A dilution series using BSA was 
prepared to generate a standard curve.  The standard and protein extracts were added to a 
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microtiter plate and diluted 1:8 with the working reagent (50:1 Reagent A to Reagent B).   
The plate was then put into the Microplate Reader Model 680 (Bio-Rad; Hercules, CA).  
While in the reader, the plate was shaken for 30 seconds, incubated at 37°C for 30 
minutes, and cooled to room temperature.  The absorbance at 560 nm was measured.  The 
average absorbance for the blank standard wells was subtracted from all the standard and 
protein extract wells.  A standard curve was created using the corrected standard values 
versus the concentration, which was used to determine the protein concentration of the 
protein extracts.  Each protein extract was diluted to 1 ug/uL. 
The diluted protein extracts were first separated using Sodium Dodecyl Sulfate 
(SDS) - polyacrylamide gel electrophoresis using the Mini-PROTEAN 3 cell (Bio-Rad; 
Hercules, CA).  The samples were prepared by adding 6X sample buffer (60% glycerol, 
300 mM Tris pH 6.8, 12 mM ethylenediaminetetraacetic acid (EDTA), 12% SDS, 864 
mM 2-mercaptoethanol, and 0.05% bromophenol blue) and boiling for 5 minutes 
followed by centrifugation at 13,000 x g for 5 minutes.  The samples were then loaded 
into a 10% polyacrylamide gel (EZ-Run Protein Solution; Fisher Scientific; Pittsburgh, 
PA) and run at 150V for 1 hour.  After separation, the proteins from the gel were 
electrophoretically transferred to a PVDF membrane (Millipore; Billerica, MA) at 100V 
and 35 mA for 1 hour.  The membranes were blocked using 5% BSA for 1 hour followed 
incubation with primary antibody.   
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Table 8. Peptide sequences used to synthesize polyclonal antibodies. 
Protein Antibody Sequence 
DnaA DnaA-1 GC-AILMKKAEDHQIHLADE 
 DnaA-2 GC-QLQARKPVHKTWDDDPQ 
DnaK-related DnaK-1 GC-VEFDVREDAKSDSNEEQ 
 DnaK-2 GC-LEHLKDAWNHANPNHKLA 
DnaJ-related DnaJ-1 GC-RKLMNEHHPDKLMAKGLP 
 DnaJ-2 GC-GHQFDKARRLSQAG 
 
 
Custom antibodies (Table 8) were designed and purchased through Bio-Synthesis 
Inc. (Lewisville, TX) for the western blot protocol.  Crude rabbit serum containing the 
antibodies was purified using Nab Spin Kits for Antibody Purification (Pierce 
Biotechnology, Rockford, IL) prior to use in western blots.  The spin columns contain a 
recombinant fusion Protein A/G that binds to various classes of IgG allowing for 
purification.  After equilibrating the columns, 500 uL of antibody containing serum was 
added to the column and it was incubated at room temperature for 10 minutes in an end 
over end mixer.  The spin column was then centrifuged at 5,000 x g for 1 minute.  The 
column was then washed three times using Binding Buffer and centrifuged at 5,000 x g 
for 1 minute.  Purified antibodies were eluted into Neutralization Buffer using IgG 
Elution Buffer followed by a 1 minute centrifugation.  The resulting antibodies were 
diluted 1:50 in Tris buffered saline with Tween-20 (TBST) and used to probe the blots 
for 1 hour, followed by five washes (5 minutes, 10 minutes, 15 minutes, 15 minutes, and 
1 hour) with TBST.   
Detection of the antibodies was performed using a 1:20,000 dilution of goat anti-
rabbit secondary antibody that is labeled with horseradish peroxidase (Pierce 
Biotechnology, Rockford, IL) followed by five washes with TBST.  The blots were 
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incubated for 1 minute in Pierce Biotechnology ECL Western Blotting Substrate 
(prepared by mixing equal parts of Detection Reagent 1 and 2).  The blot was placed 
between plastic sheet protectors removing air bubbles.  Visualization of the blot was done 
using the Chemi-Doc (Bio-Rad; Hercules, CA).  A series of thirty pictures were taken 
over an 8 hour exposure time.  The densities of the bands were analyzed using the 
QuantOne software (Bio-Rad; Hercules, CA).  All blots were completed in triplicate.  
Fold changes were calculated by comparing the expression of DnaA to the non-pandemic 
strain C&RSF and the expression of DnaJ-related protein to the pandemic strain 
VP47/BAA-238.  The significance of the fold change was determined by t-test with the 
level of significance adjusted by sequential Bonferroni to eliminate false positives (94).  
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Results 
Real Time PCR and Pandemic Group Specific PCR 
Table 9 shows the results for real time PCR of the three hemolysin genes that 
were used to identify the species and virulent strains.  All of the strains (100%) were 
positive for the species specific tlh gene.  The assays for the virulence factors indicate 
that twenty-five strains are pathogenic.  Twenty-four of the thirty strains (80%) were 
positive for tdh, and seven strains (23%) were positive for trh.  More specifically, 
eighteen strains were positive for only tdh, one strain was positive for only trh, and six 
strains were positive for both tdh and trh. 
The results for the seven pandemic group specific PCR assays are listed in Table 
10.  Thirteen of the strains were positive for all seven targets.  Six of the strains have 
already been identified as pandemic strains; these are TX 2103, VP47/BAA-238, 
VP81/BAA-239, VP185/BAA-240, VP232/BAA-241 and VP250/BAA-242 (14, 72, 116, 
127).  The seven additional strains that were positive for all seven targets were Harwood-
TDH (+), Harwood #8, MDOH-03-17282-Vp, MDOH-03-17297-Vp, MDOH-03-17298-
Vp, MDOH-03-17299-Vp and MDOH-03-17301-Vp, which indicates that these strains 
are related to pandemic strains.  Strains MDOH-04-5M732 and MDOH-04-5M734 are 
negative for all four ORF8 targets, but positive for the other pandemic strain targets 
suggesting that these two could also be pandemic strains.  However, there were seven 
strains, not previously identified as pandemic, were positive for 1 target which includes 
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targets O3MM824, PGS and F2-1 indicating that these markers are not reliable at 
identifying only pandemic strains. 
 
Table 9. Real time PCR data for strains 
used in this study. 
Strain Tdh trh Tlh 
ATCC 17802 - - + 
C&RSF + - + 
Harwood-TDH (+) + - + 
Harwood #8 + - + 
10292 + + + 
AQ 4037 - + + 
BAC 3483 + + + 
BAC 3547 - - + 
CT 02006286 + + + 
CT 02006628 - - + 
DAL 1094 - - + 
DIE12 3/16 + + + 
HC 05-01 + + + 
HC 20-01 + + + 
TX 2103 + - + 
EnvDOH-04-001 - - + 
MDOH-03-17267-Vp + - + 
MDOH-03-17282-Vp + - + 
MDOH-03-17294-Vp + - + 
MDOH-03-17297-Vp + - + 
MDOH-03-17298-Vp + - + 
MDOH-03-17299-Vp + - + 
MDOH-03-17301-Vp + - + 
MDOH-04-5M732 + - + 
MDOH-04-5M734 + - + 
VP47/BAA-238 + - + 
VP81/BAA-239 + - + 
VP185/BAA-240 + - + 
VP232/BAA-241 + - + 
VP250/BAA-242 + - + 
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Table 10. Pandemic specific PCR data for strains used in this study. 
Strain PGS O3MM824 ORF8A/B ORF8C/D VP36RF8 GS-V F2-1 
ATCC 17802 - - - - - - - 
C&RSF + - - - - - - 
Harwood-TDH (+) + + + + + + + 
Harwood #8 + + + + + + + 
10292 - - - - - - - 
AQ 4037 - - - - - - - 
BAC 3483 - + - - - - - 
BAC 3547 + - - - - - - 
CT 02006286 - + - - - - - 
CT 02006628 - - - - - - - 
DAL 1094 - - - - - - - 
DIE12 3/16 - - - - - - + 
HC 05-01 - - - - - - - 
HC 20-01 - - - - - - - 
TX 2103 + + + + + + + 
EnvDOH-04-001 + - - - - - - 
MDOH-03-17267-Vp + - - - - - - 
MDOH-03-17282-Vp + + + + + + + 
MDOH-03-17294-Vp - - - - - - - 
MDOH-03-17297-Vp + + + + + + + 
MDOH-03-17298-Vp + + + + + + + 
MDOH-03-17299-Vp + + + + + + + 
MDOH-03-17301-Vp + + + + + + + 
MDOH-04-5M732 + - - - - + + 
MDOH-04-5M734 + - - - - + + 
VP47/BAA-238 + + + + + + + 
VP81/BAA-239 + + + + + + + 
VP185/BAA-240 + + + + + + + 
VP232/BAA-241 + + + + + + + 
VP250/BAA-242 + + + + + + + 
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Serotyping 
 The thirteen strains from Florida, including the nine possible pandemic strains, 
were serotyped (Table 11).  Of these, the nine possible pandemic strains (Harwood-TDH 
(+), Harwood #8, MDOH-03-17282-Vp, MDOH-03-17297-Vp, MDOH-03-17298-Vp, 
MDOH-03-17299-Vp, MDOH-03-17301-Vp, MDOH-04-5M732 and MDOH-04-
5M734) that were identified in the Pandemic Group Specific PCR have a pandemic 
serotype with O1:K25 being the most common.  These serotyping results support the 
pandemic status of these strains.  Two strains, MDOH-03-17267-Vp and MDOH-03-
17294-Vp, were serotype O5:Kuk, a serotype recently attributed to the pandemic strain.  
The remaining two strains had one of two non-pandemic strain serotypes O1:K32 and 
O4:K37. 
 
Table 11. Serotyping results for selected strains.   
Strain Serotype1 
C&RSF O4:K37 
Harwood-TDH (+) O3:K6 
Harwood #8 O3:K6 
EnvDOH-04-001 O1:K32 
MDOH-03-17267-Vp O5:Kuk 
MDOH-03-17282-Vp O1:K25 
MDOH-03-17294-Vp O5:Kuk 
MDOH-03-17297-Vp O1:Kuk 
MDOH-03-17298-Vp O1:K25 
MDOH-03-17299-Vp O1:K25 
MDOH-03-17301-Vp O1:K25 
MDOH-04-5M732 O1:Kuk 
MDOH-04-5M734 O1:Kuk 
1 Pandemic serotypes are in boldface 
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Automated Ribotyping 
Figure 2 is the dendrogram generated from the PvuII ribotype patterns.  Five of 
the previously identified pandemic strains (VP47/BAA-238, VP81/BAA-239, 
VP185/BAA-240, VP232/BAA-241 and VP450/BAA-242) formed a major pandemic 
clustered with approximately 95-100% similarity and nine of the strains related to the 
pandemic strains (Harwood-TDH (+), Harwood #8, MDOH-03-17298-Vp, MDOH-03-
17299-Vp, MDOH-03-17301-Vp, MDOH-04-5M732, MDOH-03-17282-Vp, MDOH-03-
17297-Vp and MDOH-04-5M734) grouped in this cluster with a similarity of 85-100%.  
The pandemic strain TX 2103 was less than 65% similar to the pandemic cluster and the 
O5:Kuk strains, MDOH-03-17267-Vp and MDOH-03-17294-Vp, were less than 90% 
similar to the major pandemic cluster.  Automated ribotyping using PvuII was not able to 
group all the pandemic strains into an isolated branch.  This method was able to group the 
nine proposed pandemic strains with a majority of the known pandemic strains giving 
more evidence to the pandemic status of these strains. 
 41 
  
 
Figure 2. Cluster analysis based on PvuII RiboPrint Patterns created using UPGMA.  The 
scale above the dendrogram is in percent similarity.   
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Multilocus Sequence Typing 
MLST analysis was performed on 30 of the strains in this study (Table 12 and 
Figure 3).  Five of the strains (AQ 4037, VP81/BAA-239, VP185/BAA-240, 
VP232/BAA-241, and VP450/BAA-242) were analyzed in a previous MLST paper (15) 
and the results were replicated.  Fourteen of the strains tested were Sequence Type (ST)-
1, which has the pandemic allelic profile of 1, 1, 1, 1 for gyrB, recA, dnaE, and gnd, 
respectively, including the nine proposed pandemic strains (Table 12).  TX 2103 had a 
similar ST (5, 1, 1, 1), which adds a novel ST to the pandemic group.  In addition to the 
novel ST for the pandemic strains, additional novel STs and alleles were also identified 
(Table 13).  Seven to nine novel alleles were identified for each locus, and the sequences 
for the novel alleles are listed in Appendix B and were added to GenBank (Accession 
numbers EF524229-EF524260).   
An UPGMA dendrogram of all the known STs was generated (Figure 3).  In this 
dendrogram, the three previously identified pandemic STs (ST-1, -14, -15) cluster 
together along with the ST-20 belonging to TX 2103.  There are four other STs (ST-2, -3, 
-4, -5) that cluster near the pandemic group.  When the serotypes associated with the STs 
are examined, it is revealed that ST-1, ST-2, ST-3, ST-4, ST-5, ST-14, ST-15, and ST-20 
form an O3:K6/ Pandemic strain branch.  Furthermore, all the strains with ST-2, ST-3, 
ST-4, and ST-5 are O3:K6 strains isolated before 1995 and all the strains in the pandemic 
strain branch were isolated after 1995.   
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Table 12. MLST data for strains used in this study. 
Strain Sequence Type 
ATCC 17802 21 
C&RSF 26 
Harwood-TDH (+)2 1 
Harwood #82 1 
10292 27 
AQ 4037 4 
BAC 3483 22 
BAC 3547 19 
CT 02006286 28 
CT 02006628 23 
DAL 1094 24 
DIE12 3/16 29 
HC 05-01 30 
HC 20-01 31 
TX 21031 20 
EnvDOH-04-001 25 
MDOH-03-17267-Vp 10 
MDOH-03-17282-Vp2 1 
MDOH-03-17294-Vp 10 
MDOH-03-17297-Vp2 1 
MDOH-03-17298-Vp2 1 
MDOH-03-17299-Vp2 1 
MDOH-03-17301-Vp2 1 
MDOH-04-5M7322 1 
MDOH-04-5M7342 1 
VP47/BAA-2381 1 
VP81/BAA-2391 1 
VP185/BAA-2401 1 
VP232/BAA-2411 1 
VP250/BAA-2421 1 
1 Previously identified as pandemic strain 
2 Proposed pandemic strains 
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Table 13. Summary of Allele numbers, STs, and associated serotypes for 
V. parahaemolyticus MLST from Chowdury et al. (15) and novel Allele 
numbers and STs1. 
ST gyrB recA dnaE gnd Serotype 
1 1 1 1 1 Pandemic 
2 1 2 11 1 O3:K6 
3 1 8 2 1 O3:K6 
4 1 2 2 1 O3:K6 
5 1 2 7 1 O3:K6 
6 10 3 9 6 O1:Kuk 
7 3 3 4 2 O8:K41 
8 2 5 3 3 O8:K21, O1:Kuk 
9 6 1 5 2 O4:K8 
10 1 11 6 12 O1:K56, O5:Kuk 
11 4 3 14 5 O3:K29 
12 5 12 10 9 O4:K63 
13 12 10 1 13 O1:Kuk 
14 1 4 1 1 Pandemic 
15 1 9 1 1 Pandemic 
16 5 8 11 10 O1:Kuk 
17 13 7 13 7 O1:Kuk 
18 8 6 6 14 O1:Kuk 
19 16 17 19 18 O4:K55 
20 5 1 1 1 Pandemic 
21 1 14 15 2 O1:K1 
22 15 16 18 2 O4:K12 
23 18 19 20 2 O5:K56 
24 19 20 21 2 Unknown 
25 14 13 1 15 O1:K32 
26 5 15 16 16 O4:K37 
27 5 7 17 17 O6:K18 
28 17 18 20 19 O6:K18 
29 20 21 22 20 O1:Kuk 
30 1 8 11 21 O1:Kuk 
31 21 8 11 21 O1:Kuk 
1 Novel STs and Allele numbers are in boldface.  
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Figure 3. Cluster analysis of strains based on allelic profiles in the MLST analysis.  The 
dendrogram was constructed using UPGMA.  The scale below the dendrogram is linkage 
distance.  This dendrogram combines the STs from this paper and from Chowdhury et al. 
(15).  The STs with a ■ are pandemic and the ▲ indicate these STs belong to the pre-
1995 O3:K6 serotype. 
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Defining a Pandemic Strain 
 Table 14 summarizes the results used to determine if the thirteen strains from 
Florida are pandemic strains.  Using these methods, nine Florida strains have been 
identified as members of the pandemic strain.  Two strains are serotype O5:Kuk, a recent 
addition to the pandemic strain serotype, however these strains posses only one or none 
of the pandemic PCR targets and are not clonally related to the pandemic strain based on 
the molecular typing methods.  MLST was able to correctly classify the pandemic status 
of all the strains and was more accurate than serotyping. 
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Table 14. Summary of molecular typing methods.  This includes pandemic traits (tdh +, pandemic serotype 
and isolation after 1995), positive for pandemic group specific PCR targets, percent similar to pandemic 
group in ribotyping with PvuII, pandemic ST in MLST, and their pandemic status.  Newly identified 
pandemic strains are in boldface. 
Strain 
Pandemic 
Traits 
Pandemic 
PCR PvuII MLST Conclusions 
ATCC 17802 0 of 3 0 of 7 < 90% non-pandemic non-pandemic 
C&RSF 2 of 3 1 of 7 < 90% non-pandemic non-pandemic 
Harwood-TDH (+) 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
Harwood #8 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
10292 1 of 3 0 of 7 < 90% non-pandemic non-pandemic 
AQ 4037 1 of 3 0 of 7 < 90% non-pandemic non-pandemic 
BAC 3483 1 of 3 1 of 7 < 90% non-pandemic non-pandemic 
BAC 3547 1 of 3 1 of 7 < 90% non-pandemic non-pandemic 
CT 02006286 1 of 3 1 of 7 < 90% non-pandemic non-pandemic 
CT 02006628 1 of 3 0 of 7 < 90% non-pandemic non-pandemic 
DAL 1094 0 of 3 0 of 7 < 90% non-pandemic non-pandemic 
DIE12 3/16 1 of 3 1 of 7 < 90% non-pandemic non-pandemic 
HC 05-01 1 of 3 0 of 7 < 90% non-pandemic non-pandemic 
HC 20-01 1 of 3 0 of 7 < 90% non-pandemic non-pandemic 
TX 2103 3 of 3 7 of 7 < 90% Pandemic Pandemic 
EnvDOH-04-001 1 of 3 1 of 7 < 90% non-pandemic non-pandemic 
MDOH-03-17267-Vp 3 of 3 1 of 7 < 90% non-pandemic non-pandemic 
MDOH-03-17282-Vp 3 of 3 7 of 7 < 90% Pandemic Pandemic 
MDOH-03-17294-Vp 3 of 3 0 of 7 < 90% non-pandemic non-pandemic 
MDOH-03-17297-Vp 3 of 3 7 of 7 < 90% Pandemic Pandemic 
MDOH-03-17298-Vp 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
MDOH-03-17299-Vp 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
MDOH-03-17301-Vp 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
MDOH-04-5M732 3 of 3 3 of 7 ≥ 90% Pandemic Pandemic 
MDOH-04-5M734 3 of 3 3 of 7 ≥ 90% Pandemic Pandemic 
VP47/BAA-238 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
VP81/BAA-239 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
VP185/BAA-240 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
VP232/BAA-241 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
VP250/BAA-242 3 of 3 7 of 7 ≥ 90% Pandemic Pandemic 
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Growth Curves 
The results of the growth curves in which the non-pandemic strain C&RSF and 
pandemic strain VP47/BAA-238 were compared (Table 15) indicated that only one 
temperature had a significant influence on growth between the two strains.  Since 
multiple comparison were done, sequential Bonferroni was used to eliminate false 
positives and the adjusted level of significance used at the 0.05 level was 0.0125.  This 
significant difference was noted at 12°C using OD data (p value was less than 0.001).  At 
this temperature, the mean generation time for the non-pandemic strain (603.28 minutes) 
was close to double that of the pandemic strain (343.00 minutes).   
A graphical representation of the growth curves are depicted in Figure 4.  The 
curves using OD and CFU data for both the pandemic and non-pandemic strains at the 
higher temperatures (17°C, 30°C, 27.5°C) demonstrate standard exponential growth 
curves with no difference between the two strains.  At 12°C, the growth curves of the two 
strains demonstrate the higher exponential growth rate of the pandemic strains compared 
to the non-pandemic strain. 
 
Table 15. Mean generation time in minutes ± the standard error of three replicate growth 
curves using one strain for each group at 4 temperatures. * p < 0.05 
Measure Strain 27.5ºC 30ºC 17ºC 12ºC 
Non-pandemic 29.36 ± 1.13 29.97 ± 1.38 74.94 ± 6.49 505.06 ± 141.34 CFU 
Pandemic 30.79 ± 2.22 30.59 ± 0.21 75.31 ± 4.70 379.28 ± 105.73 
Non-pandemic 34.14 ± 1.21 34.69 ± 0.60 70.29 ± 3.26 603.28 ± 82.13* OD 
Pandemic 33.18 ± 0.91 36.24 ± 0.79 74.37 ± 2.77 343.00 ± 43.80* 
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Figure 4. Growth curves of the average CFU (Panel A) and OD600 (Panel B) values with 
standard error bars for the pandemic and non-pandemic strains over the 5 – 8 hour time 
courses at the four temperatures. 
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The differential growth at 12°C was further investigated using other strains (non-
pandemic strains ATCC 17802, 10292, AQ 4037 and NY 477; pandemic strains 
VP81/BAA-239, VP185/BAA-240, VP232/BAA-241 and VP250/BAA-242).  When 
growth curve data from additional strains was added to the previous data (Table 16 and 
Figure 5), there was significant difference in the mean generation times between the 
pandemic and non-pandemic groups using data from both plate counts (CFU) and OD.  
The growth rate of the pandemic strains was two times faster that of the non-pandemic 
strains.  Furthermore, some of the non-pandemic strains showed little to no growth 
compared to the other strains.  The graphical representation of the growth curves (Figure 
5) depicts a difference in the growth rate of the pandemic strain and non-pandemic 
strains.  The pandemic strain is displaying a more exponential growth curve than the non-
pandemic strains, which has a flatter curve. 
 
Table 16. Mean generation time in minutes ± the 
standard error of 12°C growth curves for 10 strains. * p 
< 0.05 
Measure Group Mean Generation Time 
Non-pandemic 866.63 ± 225.21* CFU 
Pandemic 342.07 ± 54.09* 
Non-pandemic 995.41 ± 175.86* OD 
Pandemic 439.87 ± 121.36* 
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Figure 5. Growth curves of the average CFU (top Panel) and OD600 (bottom Panel) values 
with standard error bars for the pandemic and non-pandemic strains over the 8 hour time 
courses at 12°C. 
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Proteomic Analysis 
Using the data from the growth curves, protein extracts from the pandemic strain 
VP47/BAA-238 and the non-pandemic strain C&RSF, each grown at 12°C, were 
compared.  Protein extracts from cell cultures grown at 30°C were used to eliminate 
proteins that were different between the strains under typical growth conditions.  
Combining the Scaffold analysis for the pandemic and non-pandemic protein samples, a 
total of 266 proteins were identified in the 30°C samples and 780 proteins were identified 
at 12°C.   
The proteins identified at 12°C were further analyzed to investigate their possible 
function in the differential growth rate of the pandemic and non-pandemic strains at 
lower temperatures.  First, the proteins that were expressed in both strains at 12°C were 
eliminated from the list.  Then using data from both the 30°C and 12°C samples, proteins 
that were expressed only in one strain at both of these temperatures were deleted because 
they indicated normal differences between the strains and not temperature related strain 
difference.  This left 214 proteins identified as being expressed in only one strain at 12°C 
but not 30°C (Appendix C).  This list was further investigated to identify proteins 
involved in cold stress (Appendix D) and three proteins of interest were identified (Table 
17).  The presence and function of these proteins in other strains during growth at 12°C 
were further investigated. 
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Table 17. Proteins of interest identified by LC-MS/MS, their function and strain 
expressed in at 12°C. 
Protein Function Strain expressed 
DnaA DNA replication during cold shock Non-pandemic 
DnaK-related Protein folding and stability, similar to a cold 
acclimation protein 
Pandemic 
DnaJ-related Unknown function but sequence is similar to a 
cold acclimation protein 
Pandemic 
 
Western Blotting 
 During the production of custom polyclonal antibodies prepared by BioSynthesis, 
the rabbits were bled four times (pre-immune, week 6, 8, and 10).  An ELISA for the 
corresponding polyclonal antibody was performed on the 6 week crude serum samples 
prior to shipment.  The ELISA results (Table 18) show that the rabbits have titers ranging 
from average to excellent for the antibodies. 
 
Table 18. ELISA results for the titers each 6 week crude rabbit serum has for 
antibodies.  Performed by BioSynthesis. 
Antibody Rabbit Titer Conclusion 
BSYN 5447 Up to 1:25600 Excellent DnaA-1 
BSYN 5448 Up to 1:25600 Excellent 
BSYN 5449 Up to 1:25600 Excellent DnaA-2 
BSYN 5450 Up to 1:25600 Excellent 
BSYN 5451 Up to 1:6400 Above average DnaK-1 
BSYN 5452 Up to 1:3200 Average 
BSYN 5453 Up to 1:3200 Average DnaK-2 
BSYN 5454 Up to 1:25600 Excellent 
BSYN 5455 Up to 1:12800 Excellent DnaJ-1 
BSYN 5456 Up to 1:3200 Average 
BSYN 5457 Up to 1:25600 Excellent DnaJ-2 
BSYN 5458 Up to 1:25600 Excellent 
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 Western blotting was used as a confirmation of the proteomics results in both 
strains used in the proteomics experiments and additional strains at both 12°C and 30°C.   
The antibodies for DnaK-related protein failed to detect the protein (data not shown).   
Both antibodies for DnaA and DnaJ-related proteins were able to bind the correctly sized 
band for each protein.  However, the antibodies DnaA-2 and DnaJ-1 were used in the 
western blot analysis because they generated cleaner blots.   
The recombinant E. coli strains DnaA-1 (expressing DnaA), DnaJ-1 (expressing 
DnaJ-related protein), and DnaK-5 (expressing DnaK-related protein) were used as 
positive controls in the blots for the specific expressed protein.  To confirm the presence 
of DnaA and DnaJ-related proteins in the bands corresponding to their molecular weight, 
DnaA-1, DnaJ-1 and JM109 protein extracts were separated using SDS:PAGE and the 
gel was stained with GelCode Blue Safe Protein Stain (Pierce Biotechnology; Rockford, 
IL).  The stained gel was sent to the Proteomics Core Facility for LC-MS/MS analysis.  
Bands corresponding to specific molecular weights (52 KDa band for DnaA and 31 KDa 
band for DnaJ-related protein) was excised and processed as previously described for LC-
MS/MS.  Appendix E details the proteins identified in these gel slices.  Both DnaA and 
DnaJ-related proteins were only identified in their recombinant strains and not in the 
JM109 strains.  Furthermore, a BLAST search of the peptide sequence used to make the 
antibodies was performed in order to identify any cross-reacting proteins.  None of these 
cross-reacting proteins were identified in the LC-MS/MS data from the gel slices 
indicating that the antibodies DnaA-2 and DnaJ-1 are reacting with either DnaA or DnaJ-
related protein respectively and not a cross-reacting protein. 
 55 
The western blot analysis of both DnaA and DnaJ-related proteins did not support 
the LC-MS/MS results.  DnaA was identified by LC-MS/MS in the non-pandemic strain 
protein extract.  In the western blot analysis for both the 12°C and 30°C protein extracts 
from additional strains, the expression of DnaA was not significantly different between 
the pandemic and non-pandemic strains either individually (Figure 6) or when grouped 
by pandemic and non-pandemic strains (Figure 7).  LC-MS/MS identified DnaJ-related 
protein in the pandemic strains’ protein extracts.  However, the western blot analysis of 
additional strains grown at 12°C and 30°C indicates that there was not a significant 
difference in the expression of DnaJ-related protein between the pandemic and non-
pandemic strains (Figures 8 and 9).  Since multiple t-tests were done on the individual 
strains (Figures 6 and 8), sequential Bonferroni was used to eliminate false positives and 
the adjusted level of significance used at the 0.05 level was 0.0056.  Sequential 
Bonferroni was not used to adjust the level of significance when testing the grouped data 
and the level of significance was 0.05 (Figures 7 and 9).  Since the results from LC-
MS/MS and western blot analysis were not supporting each other, four additional strains 
were analyzed by LC-MS/MS in order to clear up these differences.  The cold stress 
proteins identified in these strains are listed in Table 20.  DnaA was identified in both the 
pandemic and non-pandemic strains, and neither DnaJ-related nor DnaK-related proteins 
was identified in any of the protein extracts. 
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Figure 6. Western blots and graphs of the average fold change of DnaA expression 
compared to C&RSF with Standard Error bars.  DnaA-1 is the positive control and 
JM109 is the negative control.  Panel A: 12°C protein extracts and Panel B: 30°C protein 
extracts. 
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Figure 7. Graphs of the average fold change of DnaA expression for both groups 
compared to non-pandemic strains with Standard Error bars.  Panel A: 12°C protein 
extracts and Panel B: 30°C protein extracts. 
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Figure 8. Western blots and graphs of the average fold change of DnaJ-related expression 
compared to VP47/BAA-238 with Standard Error bars.  DnaJ-1 is the positive control 
and JM109 is the negative control.  Panel A: 12°C protein extracts and Panel B: 30°C 
protein extracts. 
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Figure 9. Graphs of the average fold change of DnaJ-related expression for both groups 
compared to pandemic strains with Standard Error bars.  Panel A: 12°C protein extracts 
and Panel B: 30°C protein extracts. 
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Table 19. Cold stress proteins identified by LC-MS/MS on specific strain protein extracts grown at 
12°C 
Non-pandemic Pandemic Protein name 
17802 NY 477 VP185/BAA-240 VP232/BAA-241 
Elongation factor Tu + + + + 
Replication initiator protein DnaA + + + + 
DNA gyrase subunit A + - + + 
Chaperone protein DnaK - - + + 
Chaperone protein HtpG - + + - 
Pyruvate dehydrogenase E1 
component + + - + 
Trigger factor + + + + 
Translation initiation factor IF-2 + + + + 
Protein recA + + - + 
  
 
Growth Studies using Overexpressing Recombinant Strains 
 Expression plasmids for all three proteins of interest were constructed and 
transformed into the JM109 E. coli strain.  Recombinant strains were named based on 
their initial colony number that was picked for confirmation of plasmid and insert.  
DnaA-1 is the recombinant strain with an expression plasmid for the DnaA protein.  The 
recombinant strain DnaJ-1 possesses the gene for the DnaJ-related protein and the strain 
DnaK-5 has the expression plasmid with the DnaK-related protein gene.  Growth curves 
of the recombinant strains (DnaA-1, DnaJ-1 and DnaK-5) and the control strain (JM109) 
grown at 12°C were conducted and the mean generation times were calculated (Table 
20).  To determine if growth difference between the recombinant and control strains was 
significant, the mean generation time of the control strain was compared to the mean 
generation times of the recombinant strains.  Since multiple t-tests were done, sequential 
Bonferroni was used to eliminate false positives and the adjusted level of significance 
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used at the 0.05 level was 0.017.  Using this adjusted level of significance, only the mean 
generation time for DnaK-5 (Table 20) was significantly different using CFU data (p 
value = 0.01).  The mean generation times for the recombinant DnaA-1 were faster than 
the control strain while the mean generation times for DnaJ-1 and DnaK-5 were slower.  
Figure 10 depicts the graphical representation of the growth curves in which the only 
trend difference is between JM109 and DnaK-5 using the CFU data. 
 
Table 20. Mean generation time in minutes ± the standard error of three replicate 
growth curves at 12°C using recombinant E. coli strain. * p < 0.05 
Measure JM109 DnaA-1 DnaJ-1 DnaK-5 
CFU 367.12 ±  14.99 268.96 ±  3.19 497.49 ± 103.92 548.55 ± 33.96* 
OD 1154.95 ± 198.68 367.11 ±  226.04 923.37 ± 244.48 843.31 ± 292.24 
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Figure 10. Growth curves of the average CFU (top Panel) and OD600 (bottom Panel) 
values with standard error bars for the recombinant strains (DnaA-1, DnaJ-1 and DnaK-
5) and the control strain (JM109) over the 8 hour time courses at 12°C. 
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Discussion 
Detection and Typing Methods 
Various studies investigating the rapid detection and typing of the pandemic strain 
of V. parahaemolyticus have been reported.  However, there has not been consistency on 
one method for molecular typing or an assay for PCR (4, 14, 15, 30, 36, 53, 54, 63, 65, 
79, 81, 117-120, 127).  For that reason, multiple pandemic specific PCR markers and two 
major molecular typing methods were compared to serotyping and virulence factor PCR 
data to determine the reliability of their use in classification of strains as pandemic.   
The real time PCR results for virulence factors and species specific targets 
identified pathogenic and nonpathogenic strains.  The assay for the tlh gene was designed 
as a target to identify all strains of V. parahaemolyticus (22).  This target was detected in 
100% of the isolates (Table 9) validating this assay for detection of all strains.  In order to 
identify pathogenic strains, real time PCR assays for the virulence factor genes tdh and 
trh were designed (22).  These virulence factors were detected in outbreak related strains, 
and more strains were positive for tdh (80%) than trh (23%; Table 9).  This has been 
noted in other studies of these two virulence factors (66). 
The pandemic group specific PCR results indicate that these are inadequate 
targets for identification of pandemic strains.  While thirteen strains were positive for all 
of the pandemic targets, strains MDOH-04-5M732 and MDOH-04-5M734 are missing 
ORF8 (Table 10).  This target has been reported as missing in other pandemic strains (8, 
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81, 85).  The PCR assays for ORF8A/B, ORF8C/D, VP36RF8, and GS-V were specific 
to the pandemic strains, but the assays for PGS, O3MM824 and F2-1 were positive for 
some non-pandemic strains (Table 10).  Previous studies have indicated that these were 
pandemic strain specific targets (45, 56, 65, 72, 80-82), but these results along with other 
studies identifying these PGS and toxRS/new in non-pandemic strains and toxRS/new 
(81, 88) support the conclusion that PGS, ORF8, toxRS/new, and F2-1 are not useful 
targets. 
Of the thirteen strains from Florida that were serotyped, eleven of the strains have 
a pandemic strain serotype, such as O3:K6, O1:Kuk, O5:Kuk, or O1:K25 (Table 11).  
Besides serotype, the characteristics of the pandemic stain include isolation after 1995, 
possessing the tdh and not the trh gene, and a clonal relationship determined by 
molecular typing methods (23).  Nine of the strains with a pandemic serotype are positive 
for tdh and negative for trh and are positive for at least 3 of the 7 pandemic PCR targets 
(summarized in Table 14).  However, the two O5:Kuk strains are negative for almost all 
of the pandemic group specific PCR assays.  This serotype is a newly attributed to the 
pandemic strain and only seen in strains from Asia (73).  Molecular typing methods were 
used to further define the pandemic status of these strains because these data suggest that 
current PCR markers are not sufficient to identify pandemic isolates. 
In Figure 2, a majority of the known and proposed pandemic strains clustered 
together with a similarity of 85-100% based on ribotyping patterns.  However two 
O5:Kuk strains (MDOH-03-17294-VP and MDOH-03-17267-VP) clustered with the 
pandemic strains and the pandemic strain TX 2103 was less than 65% similar to the 
pandemic cluster indicating that PvuII generated ribotype patterns do not isolate the 
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pandemic group cluster.  Therefore this restriction enzyme is not useful in identifying all 
pandemic strains as was previously demonstrated with ribotyping using BglI (14). 
MLST analysis was the most informative with respect to the pandemic identity of 
these strains (summarized in Table 14).  From Tables 12 and 13, the outbreak related 
strains that are proposed to be pandemic strains all had the ST (1, 1, 1, 1).  A pandemic 
strain not previously analyzed, TX 2103, was found to posses a novel ST to the pandemic 
group (Tables 12 and 13).  The pandemic allelic profile (1, n, 1, 1; where n is any allele) 
from Chowdhury et al. (15) should be amended to indicate that the pandemic group has at 
least 3 allele type 1s in its ST and that the gyrB and recA loci can vary.  The two O5:Kuk 
strains possess a previously reported non-pandemic ST and based on the UPGMA tree 
(Figure 3) it is more related to the non-pandemic strains.  This result indicates that MLST 
is better than serotyping at identifying pandemic strains.  The MLST analysis in this 
dissertation demonstrated novel alleles for each locus: 8 new alleles for gyrB, 9 new 
alleles for recA, 8 new alleles for dnaE, and 7 new alleles for gnd (Table 13).  In addition, 
thirteen novel STs were identified (Table 13).  The UPGMA dendrogram of the known 
STs (Figure 3) clustered the pandemic STs together in one branch and an O3:K6 branch 
was found to be closely related.  Previous studies have suggested the pandemic strains 
arose from a single O3:K6 strain (79) and the MLST dendrogram (Figure 3) was 
consistent with this theory.  These results were published as the second study to conduct 
MLST analysis on V. parahaemolyticus.  In that paper, it was suggested that a database of 
the alleles and STs should be constructed that would collect all the data in one location 
and help with future MLST analysis (23).  Another benefit to this method is that the data 
can be collected into databases and is more comparable and portable between labs than 
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are other molecular methods (26), making it a useful technique in the identification of 
pandemic strains.   
Recently a third study on MLST in V. parahaemolyticus was published which 
redesigned the method to target 7 genes spread out on both chromosomes.  The original 
method only targeted 4 genes on Chromosome I.  The redesigned method confirmed the 
pandemic strain as clonal and suggested that recombination was important to the creation 
of new clonal groups in V. parahaemolyticus (36). 
While MLST is an effective tool to identify pandemic strains of V. 
parahaemolyticus, the cost could hinder its widespread use in public health laboratories.   
DNA sequencing costs about $5 - $10 per well.  For one locus, sequencing is done in the 
forward and backward directions in separate wells.  This makes a four loci MLST assay 
about $40 - $80 per round of sequencing, which usually is repeated multiple times.  
Comparing this to the $2 - $3 per well cost of real time PCR, MLST would not be a cost 
effective method if a consistent pandemic group specific PCR assay was developed.   
Rapid identification of members of the pandemic strain is important to 
epidemiological investigation.  This study compared molecular methods used to identify 
pandemic strains and determined that MLST was the most informative and accurate of 
the methods compared.  Using this method, nine Florida outbreak related strains were 
identified as pandemic strains (Table 14) thus assisting in further research into the 
emergence of the pandemic strain since clonality is a major characterization of this strain.   
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Growth Curves 
Differences in the growth between pandemic and non-pandemic strains at various 
temperatures were investigated due to the pandemic strain’s ability to outcompete other 
strains.  The results from this study (Tables 15 and 16; Figure 4 and 5) indicate that the 
pandemic strain has a growth advantage at 12°C because the pandemic strain had a 
growth rate that was almost twice as fast as the non-pandemic strain (343.00 minutes 
versus 603.28 minutes).  This finding supports the conclusion of Nishina et al. (76) that 
the pandemic strain is better able to adapt to colder temperatures (15°C and below) than 
the non-pandemic strains.  The previous study examined the growth difference between 
the pandemic and non-pandemic strains at 15°C, 20°C and 25°C, and they found that the 
pandemic strain was growing significant faster at 15°C.  The study reported here 
complements the previous study (76).  Both of these studies used a complex media giving 
V. parahaemolyticus a nutrient rich environment, which is something the bacteria 
encounter while associated with plankton or sea-fish.  In this association, V. 
parahaemolyticus is protected from the external environment and benefits from an 
increase in nutrients (39). 
The lack of a significant difference in growth between the two strains at 27.5°C 
and 30°C was not surprising.  The diseases caused by the pandemic and non-pandemic 
strain do not differ and there has been no report of a faster onset of illness (73).  If there 
was a difference in the onset of illness caused by the pandemic strain, then one would 
expect a difference in the growth between the two strains due to one of these strains being 
able to grow faster in the host.  Therefore, the results for the growth curves at higher 
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temperatures are consistent with the onset of illness associated with the pandemic and 
non-pandemic strains.    
The pandemic strain’s ability to grow faster at lower temperatures compared to 
the non-pandemic strain may help to explain why the pandemic strain is able to out-
compete the non-pandemic strains in the temperate climate zones.  In this climate zone, 
V. parahaemolyticus undergoes a seasonal trend in which the bacteria is not found in the 
water column but is found in sediment when water temperatures drop below 15°C (3, 51, 
111).  After the water temperature raises above 15°C, V. parahaemolyticus returns to the 
water column (51, 111).  Since the pandemic strain is able to grow faster at the lower 
temperatures, more of this strain would grow compared to the non-pandemic strains 
while the bacteria overwinters in the sediment leading to an increased dispersion of the 
pandemic strain into the water column after a rise in temperatures. 
 
Analysis of Cold Stress Proteins 
Prior to investigating the differences in proteomes between the pandemic and 
non-pandemic strains at 12°C, it was hypothesized that the pandemic and non-pandemic 
strains would have difference in the expression of cold stress protein affecting growth 
difference at lower temperatures.  Three proteins related to cold stress (Table 17) were 
identified as being expressed in one strain and not the other at 12°C and these proteins 
were not expressed in either strain at 30°C.  Of these proteins, DnaA has been previously 
identified as a cold stress protein (32, 34, 37, 43, 86, 121) while the other two were 
included for further study because they were related to other cold stress proteins (Table 
17).   
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The western blot analyses of DnaA and DnaJ-related protein expression were 
unable to confirm the LC-MS/MS data because there was no corresponding significant 
difference in the expression of these two proteins between the pandemic and non-
pandemic strains.  The LC-MS/MS results identified DnaJ-related proteins in 12°C 
protein extracts from pandemic strains but not in the non-pandemic strains, and the 
reverse was found for DnaA expression (Table 17).  Western blot analysis of the 
expression of DnaA and DnaJ-related proteins showed no significant difference between 
their expression in pandemic and non-pandemic strains (Figures 6 - 9).  The protein 
extracts of four additional strains grown at 12°C were analyzed by LC-MS/MS (Table 
19).  DnaA was identified in all the strains supporting the western blot results.  DnaJ-
related and DnaK-related proteins were not identified in any of the protein extracts, 
which disagreed with both the original LC-MS/MS and western blot results.  The 
inability of the western blot analysis to confirm the original LC-MS/MS results could be 
caused by differences in the two techniques.  Western blot analysis is more sensitive than 
mass spectroscopy especially when dealing with a complex protein mixture.  This is 
possibly due to higher abundant signals overshadowing lower signals in mass 
spectroscopy analysis (24).  The lower sensitivity of mass spectroscopy in dealing with 
the total protein samples could have caused the failure for LC-MS/MS to detect either 
DnaA or DnaJ-related protein in samples from the pandemic and non-pandemic strains 
respectively. 
The hypothesis tested was that the expression of cold stress proteins would differ 
between the pandemic and non-pandemic strains relating to the faster growth of the 
pandemic strain at lower temperatures.  The western blot results indicate that this 
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hypothesis may be false, but the protein extracts used in the LC-MS/MS and western blot 
analyses do not match the same time period as the growth curves.  For LC-MS/MS and 
western blot, fresh cultures were started using an inoculation from overnight culture 
grown at 12°C.  This culture was allowed to grow at 12°C for two to three days before 
proteins were extracted.  Comparatively for the 12°C growth curves, a fresh culture was 
started using an inoculation from an overnight culture grown at 12°C and data for the 
growth curves was collected for an 8 hour period after the overnight growth.  Protein 
expression during the 8 hours period after an initial overnight growth at 12°C should be 
investigated for difference in cold stress proteins between the pandemic and non-
pandemic strains before this stress pathway can be ruled out as the reason for the 
pandemic growth advantage. 
For the growth curves using the expression recombinant strains, it was 
hypothesized that overexpressing the proteins of interest would increase the growth rate 
in strains DnaJ-1 and DnaK-5 and decrease the growth rate in strain DnaA-1 compared to 
the control strain.  Although the ideal experiment would have been making a V. 
parahaemolyticus expression recombinant, the use of E. coli as a model system and the 
detailed research into cold stress in E. coli made it a viable surrogate.  However, DnaK-5 
had a significantly slower mean generation time than JM109 (Table 20 and Figure 10).  
The growth curve results do not support the initial LC-MS/MS results in which DnaK-
related protein was identified in the faster growing pandemic strain.  If DnaK-related 
protein was involved in the pandemic strains ability to grow faster at lower temperatures, 
then the recombinant strain would display a faster growth rate.  Furthermore, these results 
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indicate that these proteins do not cause the faster growth of the pandemic strain at lower 
temperatures.   
As previously mentioned, the method used in the proteomics experiment had a 
bias towards protein expression later in the cold stress pathway, possibly excluding 
proteins expressed early in the pathway.  Due to the amount of culture needed for the 
protein extraction method, cultures at 12°C were grown for 2 – 3 days while the growth 
differences seen in the original growth curves were during an 8 hour period after the 
transfer from an overnight culture to fresh media.  Both strains were grown to OD600 of 
0.8 to 1.0 and the pandemic strain reached this value one day faster than the non-
pandemic strain.  In E. coli, cold stress changes from shock to acclimation in 4 hours 
after the downshift in temperature (32, 34, 86), and a similar length of lag period may 
exist in V. parahaemolyticus.  The difference in the growth of the pandemic and non-
pandemic strain could occur during the change from cold shock to cold accumulation, 
and if this is the case, then the protein extractions after the switch would miss this 
difference. 
The growth curve of the DnaA expression strain was faster than the JM109 
growth curves, which is opposite the pattern seen in the non-pandemic V. 
parahaemolyticus strains.  This difference may be due to the function of DnaA in 
replication.  Twenty DnaA-ATP molecules are needed to initiation replication (102), thus 
overexpression would make more molecules available and one would suggest that this 
would lead to faster replication of DNA and cell division.  However, studies have shown 
that the overexpression of DnaA does lead to increased DNA replication but not cell 
division (122).  Furthermore, this non-significant increase in growth compared to the 
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JM109 cells may be due to lack of reproducibility of consistent growth in the JM109 
cells. 
 
Future Studies 
The pandemic strain has a faster growth rate at lower temperatures that is 
continually observed hours to days after growth at lower temperatures.  Therefore, it is 
proposed that the pandemic strain has an advantage with the regulation of cold stress that 
ultimately leads to a faster growth rate after acclimation to the lower temperatures.  In 
order to test this theory further experimentation needs to be done to better understand 
cold stress in V. parahaemolyticus. Little is known about cold stress in V. 
parahaemolyticus as compared to E. coli leaving some interesting aspects to investigate.  
After cold shock is induced, E. coli enters a 4 hour lag period (32, 34, 86).  The lag 
period of V. parahaemolyticus should be determined and compared between the 
pandemic and non-pandemic strains.   
Another area of investigation would be the identification of V. parahaemolyticus 
cold stress proteins.  A difference in the time period used between the initial growth 
studies and the proteomics experiment was noted.  Since the difference in growth was 
seen in an 8 hour period following growth as an overnight culture, this time scale should 
be used.  Due to the slow growth at 12°C, a larger starting culture is required.  This 
culture would be gently decreased in temperature to 12°C for overnight acclimation and 
then transferred to fresh media for an 8 hour growth period.  Samples for protein analysis 
can be taken at specific times during the process.  A DNA microarray of known cold 
stress proteins monitoring expression during the same period may be useful. Using a 
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DNA microarray, the transcriptome of E. coli wild type and quadruple csp-deletion 
strains after temperature downshift was analyzed and new genes were identified as being 
induced during cold shock (89).    
The sequences of known cold stress genes and any new genes identified through 
the above methods should be compared between the pandemic and non-pandemic strains.  
Only a pandemic V. parahaemolyticus genome sequence has been completed; therefore, 
the individual sequencing of these genes would have to be done until a non-pandemic 
genome sequence is completed.  The pandemic genome contains two copies of CspA, one 
on each chromosome, that have 74% similar in their protein sequence.  The possession of 
two major cold shock proteins has been shown in V. cholerae and V. vulnificus (21, 61).  
Investigation into whether both of the V. parahaemolyticus CspA genes are necessary for 
the cold stress response should be done.   
Additional research to discover pandemic markers for the identification of 
pandemic strains using PCR is needed.  Previous studies have suggested pandemic group 
specific targets for PCR assays (8, 45, 56, 65, 72, 80-82, 85), but further analysis has 
shown them to be ineffective.  In order to find better pandemic group specific PCR 
targets, the genome of the non-pandemic strain should be sequenced.  Then both the 
genomes of the pandemic and non-pandemic strains can be searched for difference that 
can be further tested for their use as a pandemic marker.  The use of a single gene or 
multiplex PCR assay would be a faster method and less expensive than MLST. 
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Conclusion and Biological Relevance 
This dissertation details the research into various aspects of the pandemic strain of 
V. parahaemolyticus.  It was reported that MLST was more accurate than serotyping, 
automated ribotyping and pandemic group specific PCR at identifying pandemic strains.  
This method was able to identify nine Florida related outbreak strains as pandemic 
strains.  Further experiments investigated the growth differences of the pandemic and 
non-pandemic strains at different temperatures.  From this it was determined that the 
pandemic strains grow faster at 12°C and three cold stress related proteins were identified 
as being expressed in one strain and not another using proteomic methods.  However, 
only one of these proteins caused a significant difference in growth using expression 
recombinant E. coli strains, but the difference was slower and opposite what was 
expected.   
Accurate identification of members of the pandemic strain is important for 
understanding and attributing outbreaks to this strain.  Previous definitions included 
serotype, year of isolation and possession of specific virulence factors, but inclusion of 
molecular typing methods added another category.  Many molecular typing methods have 
shown the clonal nature of this strain, but some have not been as useful (4, 14, 15, 36, 81, 
117-119, 127).  MLST was found to be the most accurate of the methods compared in 
this study.  Benefits of this method also include portability between labs and 
accumulation of data into an online database (17, 26, 103, 113).  The benefits of MLST 
and its ability to identify pandemic strains make it an attractive addition to PCR for 
virulence factors. 
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Research into the emergence and differences of pandemic V. parahaemolyticus 
has occurred since it was discovered, but it is still not known how this strain evolved to 
become a dominate strain (73).  The results reported here give a possible explanation to 
this phenomenon.  The pandemic strain can grow faster than the non-pandemic strain at 
lower temperatures which can lead to more of the pandemic strain being released into the 
water column when the water temperatures increase.  After a rise in temperature, the 
growth advantage of the pandemic strain disappears, but more of that strain would be 
available to resume normal growth.  Further research into understanding this growth 
advantage was proposed and should be undertaken. 
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Appendix A. List of all Vibrio parahaemolyticus strains used in this study 
 
Table A-1. List of all Vibrio parahaemolyticus strains used in this study 
Strain Serotype Source Year of Isolation 
ATCC 17802 O1:K1 Japan (E) 1965 
C&RSF O4:K37 Florida (E) 2002 
Harwood-TDH (+) O3:K6 Florida (E) 2003 
Harwood #8 O3:K6 Florida (E) 2003 
10292 O6:K18 Washington (C) 1997 
AQ 4037 O3:K6 Maldives (C) 1985 
BAC 3483 O4:K12 New York (C)  
BAC 3547 O4:K55 New York (C) 1998 
CT 02006286 O6:K18 Connecticut (C)  
CT 02006628 O5:K56 Connecticut (C)  
DAL 1094     
DIE12 3/16 O1:Kuk Alabama (E)  
HC 05-01 O1:Kuk Washington (E)  
HC 20-01 O1:Kuk Washington (E)  
NY 477 O4:K8 New York (E) 1977 
TX 2103 O3:K6 Texas (C) 1998 
EnvDOH-04-001 O1:K32 Florida (E) 2004 
MDOH-03-17267-Vp O5:Kuk Florida (C) 2003 
MDOH-03-17282-Vp O1:K25 Florida (C) 2003 
MDOH-03-17294-Vp O5:Kuk Florida (C) 2003 
MDOH-03-17297-Vp O1:Kuk Florida (C) 2003 
MDOH-03-17298-Vp O1:K25 Florida (C) 2003 
MDOH-03-17299-Vp O1:K25 Florida (C) 2003 
MDOH-03-17301-Vp O1:K25 Florida (C) 2003 
MDOH-04-5M732 O1:Kuk Florida (C) 2004 
MDOH-04-5M734 O1:Kuk Florida (C) 2004 
VP47/BAA-238 O3:K6 India (C) 1996 
VP81/BAA-239 O3:K6 India (C) 1996 
VP185/BAA-240 O1:Kuk India (C) 1997 
VP232/BAA-241 O4:K68 India (C) 1998 
VP250/BAA-242 O1:Kuk India (C) 1998 
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Appendix B. Sequences for the novel MLST Alleles 
 
dnaE Alleles 
>dnaE-15 allele 
ACGTGACCGTTCGTTTGGGTGAATACTTCTTGCCAGCCTTCCCAACAGAAGGG
ATGGAAGAAACTGAATTCTTGGTCATGAAGTCGCGCGAAGGTTTGGAAGAGC
GTCTAGAGTTCCTATTCCCTGATGAAGAAGAGCGCAAAAAGCGCCGTCCAGA
ATACGACGAGCGTTTACAAATCGAACTCGACGTAATCAACCAAATGGGGTTC
CCAGGCTACTTCTTGATCGTAATGGAGTTCATCCAGTGGTCGAAAGACAACG
CGATTCCAGTCGGTCCTGGTCGTGGTTCGGGTGCCGGTTCTTTGGTGGCCTAC
GCGCTGAAAATCACCGATCTTGATCCGCTTGAATATGACTTGCTCTTCGAACG
TTTCTTGAACCCAGAACGTGTATCCATGCCCGATTTCGACGTCGACTTTTGTA
TGGATAAGCGTGACCAAGTGATTGATCACG 
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Appendix B (Continued) 
>dnaE-16 allele 
ACGTGACCGTTCGTTTAGGTGAATACTTCTTGCCAGCCTTCCCAACAGAAGGG
ATGGAAGAAACTGAATTCTTGGTCATGAAGTCGCGTGAAGGTTTGGAAGAGC
GTCTAGAGTTCCTATTCCCTGATGAAGAAGAGCGCAAAAAGCGCCGTCCAGA
ATACGACGAGCGTTTACAAATCGAACTCGACGTAATCAACCAAATGGGGTTC
CCAGGCTACTTCTTGATCGTAATGGAGTTCATCCAGTGGTCGAAAGACAACG
CGATTCCAGTCGGTCCTGGTCGTGGTTCGGGTGCCGGTTCTTTGGTGGCCTAC
GCGCTGAAAATCACCGATCTTGATCCGCTTGAATATGACTTGCTCTTCGAACG
TTTCTTGAACCCAGAACGTGTATCCATGCCCGATTTCGACGTCGACTTTTGTA
TGGATAAGCGTGACCAAGTGATTGATCACG 
 
>dnaE-17 allele 
ACGTGACCGTTCGTTTAGGTGAATACTTCTTGCCCGCCTTCCCAACAGAAGGG
ATGGAAGAAACTGAATTCTTGGTCATGAAGTCGCGCGAAGGTTTGGAAGAGC
GTCTAGAGTTCCTATTCCCTGATGAAGAAGAGCGCAAAAAGCGCCGTCCAGA
ATACGACGAGCGTTTACAAATCGAACTCGACGTAATCAACCAAATGGGGTTC
CCAGGCTACTTCTTGATCGTAATGGAGTTCATCCAGTGGTCGAAAGACAACG
CTATTCCAGTCGGTCCTGGTCGTGGTTCGGGTGCCGGTTCTTTGGTGGCCTAT
GCGCTGAAAATCACCGATCTTGATCCGCTTGAATATGACTTGCTCTTCGAACG
TTTCTTGAACCCAGAACGTGTATCCATGCCCGATTTCGACGTCGACTTTTGTA
TGGATAAGCGTGACCAAGTGATTGATCACG 
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Appendix B (Continued) 
>dnaE-18 allele 
ACGTGACCGTTCGTTTAGGTGAATACTTCTTGCCAGCCTTTCCAACAGAAGGG
ATGGAAGAAACTGAATTCTTGGTCATGAAGTCGCGCGAAGGTTTGGAAGAGC
GTCTAGAGTTCCTATTCCCTGATGAAGAAGAGCGCAAAAAGCGCCGTCCAGA
ATACGACGAGCGTTTACAAATCGAACTCGACGTAATAAACCAAATGGGGTTC
CCAGGCTACTTCTTGATCGTAATGGAGTTCATTCAGTGGTCGAAAGACAACG
CGATTCCAGTCGGTCCTGGTCGTGGTTCGGGTGCCGGTTCTTTGGTGGCCTAC
GCGCTGAAAATCACCGATCTTGATCCGCTTGAATATGACTTGCTCTTCGAACG
TTTCTTAAACCCAGAACGTGTATCCATGCCCGATTTCGACGTCGACTTTTGTA
TGGATAAGCGTGACCAAGTGATTGATCACG 
 
>dnaE-19 allele 
ACGTGACCGTTCGTTTGGGTGAATACTTCTTGCCAGCCTTCCCAACAGAAGGG
ATGGAAGAAACTGAATTCTTGGTCATGAAGTCGCGCGAAGGTTTGGAAGAGC
GTCTAGAGTTCCTATTCCCTGATGAAGAAGAGCGCAAAAAGCGCCGTCCAGA
ATACGACGAGCGTTTACAAATCGAACTCGACGTAATCAACCAAATGGGGTTC
CCAGGCTACTTCTTGATCGTAATGGAGTTCATACAGTGGTCGAAAGACAACG
CGATTCCAGTCGGTCCTGGTCGTGGTTCGGGTGCCGGTTCTTTGGTGGCCTAC
GCGCTGAAAATCACCGATCTTGATCCGCTTGAATATGACTTGCTCTTCGAACG
TTTCTTGAACCCAGAACGTGTATCCATGCCCGATTTCGACGTCGACTTTTGTA
TGGATAAGCGTGACCAAGTGATTGATCACG 
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Appendix B (Continued) 
>dnaE-20 allele 
ACGTGACCGTTCGTTTGGGGGAATACTTCTTGCCAGCCTTCCCAACAGAAGG
GATGGAAGAAACTGAATTCTTGGTCATGAAGTCGCGCGAAGGTTTGGAAGAG
CGTCTAGAGTTCCTATTCCCTGATGAAGAAGAGCGCAAAAAGCGCCGTCCAG
AATACGACGAGCGTTTACAAATCGAACTCGACGTAATCAACCAAATGGGGTT
CCCAGGCTACTTCTTGATCGTAATGGAGTTCATCCAGTGGTCGAAAGACAAC
GCGATTCCAGTCGGTCCTGGTCGTGGTTCGGGTGCCGGCTCTTTGGTGGCCTA
CGCGCTGAAAATCACCGATCTTGATCCGCTTGAATATGACTTGCTCTTCGAAC
GTTTCTTGAACCCAGAACGTGTATCCATGCCCGATTTCGACGTCGACTTTTGT
ATGGATAAGCGTGACCAAGTGATTGATCACG 
 
>dnaE-21 allele 
ACGTGACCGTTCGTTTAGGTGAATACTTCTTGCCAGCCTTCCCAACAGAAGGG
ATGGAAGAAACTGAATTCTTGGTCATGAAGTCACGAGAAGGTTTGGAAGAGC
GTCTAGAGTTCCTATTCCCTAATGAAGAAGAGCGCAAAAAGCGCCGTCCAGA
ATACGACGAGCGTTTACAAATCGAACTCGACGTAATCAACCAAATGGGGTTC
CCAGGCTACTTCTTGATCGTAATGGAGTTCATCCAGTGGTCGAAAGACAACG
CGATTCCAGTCGGTCCTGGTCGTGGTTCGGGTGCCGGTTCTTTGGTGGCCTAC
GCGCTGAAAATCACCGATCTTGATCCGCTTGAATATGACTTGCTCTTCGAACG
TTTCTTGAACCCAGAACGTGTATCCATGCCCGATTTCGACGTCGACTTTTGTA
TGGATAAGCGTGACCAAGTGATTGATCACG 
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Appendix B (Continued) 
>dnaE-22 allele 
ACGTGACCGTTCGTTTAGGTGAATACTTCTTGCCAGCCTTCCCAACAGAAGGG
ATGGAAGAAACTGAATTCTTGGTCATGAAGTCGCGCGAAGGTTTGGAAGAGC
GTCTAGAGTTCCTATTCCCTGATGAAGAAGAGCGCAAAAAGCGCCGTCCAGA
ATACGACGAGCGTTTACAAATCGAACTCGACGTAATCAACCAAATGGGGTTC
CCAGGCTACTTCTTGATCGTAATGGAGTTCATCCAGTGGTCGAAAGACAACG
CGATTCCAGTCGGTCCTGGTCGTGGTTCGGGTGCCGGCTCTTTGGTGGCCTAC
GCGCTGAAAATCACCGATCTTGATCCGCTTGAATATGACTTGCTCTTCGAACG
TTTCTTGAACCCAGAACGTGTATCCATGCCCGATTTCGACGTCGACTTTTGTA
TGGATAAGCGTGACCAAGTGATTGATCACG 
 
gnd Alleles 
>gnd-15 allele 
TTCCAAGGTATTTCTGCGAAAACTGACGCAGGCGAGCCTTGTTGTGATTGGGT
TGGTAACGATGGTGCGGGTCACTTCGTTAAGATGGTCCACAACGGCATCGAA
TACGGCGACATGCAGCTGATCACTGAAGCTTACCAGTTCATGAAAGACGGTC
TTGGTATGTCTGCAGATGAAATGCAAGCGGTATTCGCTGAGTGGAACAACAC
TGAGCTAAATAGCTACCTAGTTGAAATCACCGCTGACATCCTTGGCTACAAA
GACGAAGATGGTGAACCTCTAGTTGAAAAAATCCTAGACACTGCTGGCCAAA
AAGGTACAGGTAAATGGACGGGTATCAACGCACTAGACCTAGGTATTCCACT
AACGCTTATCTCTGAGTCAGTATTCTCTCGTTGCCTATCTGCACTAAAAGATC
AACGTGTTGAAGCCGAGAAACTGTTCGGTAAG 
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Appendix B (Continued) 
>gnd-16 allele 
TTCCAAGGTATTTCTGCGAAAACTGATGCAGGCGAGCCATGTTGTGATTGGGT
TGGTAACGATGGTGCAGGTCACTTCGTGAAGATGGTTCACAACGGCATCGAA
TATGGCGACATGCAGCTGATCACTGAAGCTTACCAGTTCATGAAAGACGGCC
TTGGTATGTCTGCAGATGAAATGCAAGCGGTATTCGCTGAGTGGAACAACAC
TGAGCTAAATAGCTACCTAGTTGAAATCACCGCTGACATCCTTGGCTACAAA
GACGAAGATGGTGAACCTCTAGTTGAAAAAATCCTAGACACTGCTGGCCAAA
AAGGTACAGGTAAATGGACGGGTATCAACGCACTAGACCTAGGTATTCCACT
AACGCTTATCTCTGAGTCAGTATTCTCTCGTTGCCTATCTGCACTAAAAGATC
AACGTGTTGAAGcTGAGAAACTGTTCGGTAAG 
 
> gnd-17 allele 
TTCCAAGGTATTTCTGCGAAAACTGACGCAGGCGAGCCATGTTGTGATTGGG
TTGGTAACGATGGTGCAGGTCACTTCGTGAAGATGGTTCACAACGGCATCGA
ATATGGCGACATGCAGCTGATCACTGAAGCTTACCAGTTCATGAAAGACGGT
CTTGGTATGTCTGCAGATGAAATGCAAGCGGTATTCGCTGAGTGGAACAACA
CTGAGCTAAATAGCTACCTAGTTGAAATCACCGCTGACATCCTTGGCTACAA
AGACGAAGATGGTGAACCTCTAGTTGAAAAAATCCTAGACACTGCTGGCCAA
AAAGGTACAGGTAAATGGACGGGTATCAACGCACTAGACCTAGGTATTCCAC
TAACGCTTATCTCTGAGTCAGTATTCTCTCGTTGCCTATCTGCACTGAAAGAC
CAACGTGTTGAAGCTGAGAAACTGTTCGGTAAG 
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Appendix B (Continued) 
>gnd-18 allele 
TTCCAAGGTATTTCTGCGAAAACTGACGCAGGCGAGCCATGTTGTGATTGGG
TTGGTAACGATGGTGCAGGTCACTTCGTGAAGATGGTTCACAACGGCATCGA
ATATGGCGACATGCAGCTGATCACTGAAGCTTACCAGTTCATGAAAGACGGT
CTTGGTATGTCTGCAGATGAAATGCAAGCGGTATTCGCTGAGTGGAACAACA
CTGAGCTAAATAGCTACCTAGTTGAAATCACCGCTGACATCCTTGGCTACAA
AGACGAAGATGGTGAACCTCTAGTTGAAAAAATCCTAGACACTGCTGGCCAA
AAAGGTACAGGTAAATGGACGGGTATCAACGCACTAGACCTAGGTATTCCAC
TAACGCTTATCTCTGAGTCAGTATTCTCTCGTTGCCTATCTGCACTAAAAGAT
CAACGTGTTGAAGcTGAGAAACTGTTCGGTAAG 
 
>gnd-19 allele 
TTCCAAGGTATTTCTGCGAAAACTGACGCTGGCGAGCCTTGTTGTGATTGGGT
TGGTAACGATGGTGCAGGTCACTTCGTTAAGATGGTTCACAACGGCATCGAA
TACGGCGACATGCAGCTGATCACTGAAGCTTACCAGTTCATGAAAGACGGCC
TTGGTATGTCTGCAGATGAAATGCAAGCGGTATTCGCTGAGTGGAACAACAC
TGAGCTGAATAGCTACCTAGTTGAAATCACGGCTGACATCCTTGGCTACAAA
GACGAAGATGGTGAACCTCTAGTTGAAAAAATCCTAGACACTGCTGGCCAAA
AAGGTACAGGTAAATGGACGGGTATCAACGCACTAGACCTAGGTATTCCACT
AACGCTTATCTCTGAGTCAGTATTCTCTCGTTGCCTATCTGCACTAAAAGATC
AACGTGTTGAAGCTGAGAAACTGTTCGGTAAG 
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Appendix B (Continued) 
> gnd-20 allele 
TTCCAAGGCATTTCTGCAAAAACTGACGCTGGCGAGCCTTGTTGTGATTGGGT
TGGTAACGATGGTGCAGGTCACTTCGTGAAGATGGTTCACAACGGCATCGAG
TATGGCGACATGCAGCTGATCACTGAAGCTTACCAGTTCATGAAAGAAGGTC
TTGGTATGTCTGCAGATGAAATGCAAGCGGTATTCGCTGAGTGGAACAACAC
TGAGCTAAATAGCTACCTAGTTGAAATCACAGCTGACATCCTTGGCTACAAA
GACGAAGATGGTGAACCTCTAGTTGAAAAAATCCTAGACACTGCTGGCCAAA
AAGGTACAGGTAAATGGACGGGTATCAACGCACTAGACCTAGGTATTCCACT
AACGCTTATCTCTGAGTCAGTATTCTCTCGTTGCCTATCTGCACTAAAAGATC
AACGTGTTGAAGCTGAGAAACTGTTCGGTAAG 
 
> gnd-21 allele 
TTCCAAGGTATTTCTGCGAAAACTGACGCAGGCGAGCCATGTTGTGATTGGG
TTGGTAACGATGGTGCAGGTCACTTCGTGAAGATGGTTCACAACGGCATCGA
ATATGGCGACATGCAGCTGATCACTGAAGCTTACCAGTTCATGAAAGACGGT
CTTGGTATGTCTGCAGATGAAATGCAAGCGGTATTCGCAGAGTGGAACAACA
CTGAGCTAAATAGCTACCTAGTTGAAATCACCGCTGACATCCTTGGCTACAA
AGACGAAGATGGTGAACCTTTAGTTGAAAAAATCCTAGACACTGCTGGCCAA
AAAGGTACAGGTAAATGGACGGGTATCAACGCACTAGACCTAGGTATTCCAC
TAACGCTTATCTCTGAGTCAGTATTCTCTCGTTGCCTATCTGCACTAAAAGAT
CAACGTGTTGAAGCTGAGAAACTGTTCGGTAAG 
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Appendix B (Continued) 
gyrB Alleles 
>gyrB-14 allele 
ATGCAGTGGAACGATGGTTTCCAAGAGAACATCTTCTGTTTCACCAACAACA
TTCCACAGCGCGATGGTGGTACTCACCTTGCTGGTTTCCGTGCGGCACTAACA
CGTACGCTAAACAGCTTTATGGATAAAGAAGGCTTCTCGAAGAAAGCGAAAA
CAGCAACGTCAGGCGACGATGCGCGTGAAGGTTTGACAGCCGTTGTTTCGGT
AAAAGTGCCTGATCCAAAATTCTCGAGCCAAACCAAAGACAAACTGGTTTCT
TCTGAAGTGAAATCAGCGGTTGAATCGGCGATGGGTGAGAAGCTATCTGAGT
TCTTGGTAGAAAACCCAAGTGAAGCGAAGATGGTTTGTTCGAAAATCATCGA
TGCAGCACGTGCACGTGAAGCCGCACGTAAAGCGCGTGAAATGACTCGTCGT
AAAGGCGCGCTAGACCTAGCTGGCCTACCAGGC 
 
>gyrB-15 allele 
ATGCAGTGGAACGATGGTTTCCAAGAGAACATCTTCTGTTTCACCAACAACA
TTCCACAGCGCGATGGTGGTACTCACCTTGCTGGTTTCCGTGCGGCACTAACA
CGTACGCTAAACAGCTTTATGGATAAAGAAGGCTTCTCGAAGAAAGCGAAAA
CGGCAACGTCAGGCGACGATGCGCGTGAAGGTTTGACTGCCGTTGTTTCAGT
AAAAGTGCCTGATCCAAAATTCTCGAGCCAAACCAAAGACAAACTGGTTTCT
TCTGAAGTGAAATCAGCGGTTGAATCGGCGATGGGTGAGAAGCTATCTGAGT
TCTTGGTCGAAAACCCAAGCGAAGCGAAGATGGTTTGTTCGAAAATCATCGA
TGCAGCACGTGCACGTGAAGCCGCACGTAAAGCGCGTGAAATGACTCGTCGT
AAAGGCGCGCTAGACCTAGCAGGCCTACCAGGC 
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Appendix B (Continued) 
>gyrB-16 allele 
ATGCAGTGGAACGATGGTTTCCAAGAGAACATCTTCTGTTTCACCAACAACA
TTCCACAGCGCGATGGTgGTACTCACCTTGCTGGTTTCCGTGCGGCACTAACA
CGTACGCTAAACAGCTTTATGGATAAAGAAGGCTTCTCGAAGAAAGCGAAAA
CAGCAACGTCAGGCGACGATGCGCGTGAAGGTTTGACAGCCGTTGTTTCGGT
AAAAGTGCCTGATCCAAAATTCTCGAGCCAAACCAAAGACAAACTGGTTTCT
TCTGAAGTGAAATCAGCGGTTGAATCGGCGATGGGTGAGAAGCTATCTGAGT
TCTTGGTCGAAAACCCAAGCGAAGCGAAGATGGTTTGTTCGAAAATCATCGA
TGCAGCACGTGCACGTGAAGCCGCACGTAAAGCGCGTGAAATGACTCGTCGT
AAAGGCGCGCTAGACCTAGCAGGCCTACCAGGC 
 
>gyrB-17 allele 
ATGCAGTGGAACGATGGTTTCCAAGAGAACATCTTCTGTTTCACCAACAACA
TTCCACAGCGCGATGGTGGTACTCACCTTGCTGGTTTCCGTGCGGCACTAACA
CGTACGCTAAACAGCTTTATGGATAAAGAAGGCTTCTCGAAGAAAGCGAAAA
CAGCAACGTCAGGCGACGATGCGCGTGAAGGTTTGACAGCCGTTGTTTCAGT
AAAAGTGCCTGATCCAAAATTCTCGAGCCAAACCAAAGACAAACTGGTTTCT
TCTGAAGTGAAATCAGCGGTTGAATCGGCGATGGGTGAGAAGCTATCTGAGT
TCTTGGTCGAAAACCCAAGCGAAGCGAAGATGGTTTGTTCGAAAATCATCGA
TGCAGCACGTGCACGTGAAGCCGCACGTAAAGCGCGTGAAATGACTCGTCGT
AAAGGCGCGCTAGACCTAGCAGGCCTACCAGGC 
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Appendix B (Continued) 
>gyrB-18 allele 
ATGCAGTGGAACGATGGTTTCCAAGAGAACATCTTCTGTTTCACCAACAACA
TTCCACAGCGCGATGGTGGTACTCACCTTGCTGGTTTCCGTGCGGCACTAACA
CGTACGCTAAACAGCTTTATGGATAAAGAAGGCTTCTCGAAGAAAGCGAAAA
CAGCAACGTCAGGCGACGATGCGCGTGAAGGTTTGACAGCCGTTGTTTCGGT
AAAAGTGCCTGATCCAAAATTCTCGAGCCAAACCAAAGACAAGCTGGTTTCT
TCTGAAGTGAAATCAGCGGTTGAATCGGCGATGGGTGAGAAGCTATCTGAGT
TCTTGGTCGAAAACCCAAGCGAAGCGAAGATGGTTTGTTCGAAAATCATCGA
TGCAGCACGTGCACGTGAAGCCGCACGTAAAGCGCGTGAAATGACTCGTCGT
AAAGGCGCGCTAGACCTAGCAGGCCTACCAGGC 
 
>gyrB-19 allele 
ATGCAATGGAACGATGGTTTCCCAGAGAACATCTTCTGTTTCACCAACAACAT
TCCACAGCGCGATGGTGGTACTCACCTTGCTGGTTTCCGTGCGGCACTAACAC
GTACGCTAAACAGCTTTATGGATAAAGAAGGCTTCTCGAAGAAAGCGAAAAC
GGCAACGTCAGGCGACGATGCGCGTGAAGGTTTGACTGCCGTTGTTTCAGTA
AAAGTGCCTGATCCAAAATTCTCGAGCCAAACCAAAGATAAACTGGTTTCTT
CTGAAGTAAAATCAGCGGTTGAATCGGCGATGGGTGAGAAGCTATCTGAGTT
CTTGGTCGAAAACCCAAGCGAAGCGAAGATGGTTTGTTCGAAAATCATCGAT
GCAGCACGTGCACGTGAAGCCGCACGTAAAGCGCGTGAAATGACTCGTCGTA
AAGGTGCGCTAGACCTAGCAGGCCTACCAGGC 
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Appendix B (Continued) 
>gyrB-20 allele 
ATGCAGTGGAACGATGGTTTCCAAGAGAACATCTTCTGTTTCACCAACAACA
TTCCACAGCGCGATGGTGGTACTCACCTTGCTGGTTTCCGTGCGGCACTAACA
CGTACGCTAAACAGCTTTATGGATAAAGAAGGCTTCTCGAAGAAAGCGAAAA
CAGCAACGTCAGGCGACGATGCGCGTGAAGGTTTGACTGCCGTTGTTTCAGT
AAAAGTGCCTGATCCAAAATTCTCGAGCCAAACTAAAGACAAACTGGTTTCT
TCTGAAGTGAAATCAGCGGTTGAATCGGCGATGGGTGAGAAGCTATCTGAGT
TCTTGGTCGAAAACCCAAGCGAAGCGAAGATGGTTTGTTCGAAAATCATCGA
TGCAGCACGTGCACGTGAAGCTGCACGTAAAGCGCGTGAAATGACTCGTCGT
AAAGGCGCGCTAGACCTAGCAGGCCTACCAGGA 
 
>gyrB-21 allele 
ATGCAGTGGAACGATGGTTTCCAAGAGAACATCTTCTGTTTCACCAACAACA
TTCCACAGCGCGATGGTGGTACTCACCTTGCTGGTTTCCGTGCGGCACTAACA
CGTACGCTAAACAGCTTTATGGATAAAGAAGGCTTCTCGAAGAAAGCGAAAA
CGGCAACGTCAGGCGACGATGCGCGTGAAGGTTTGACAGCCGTTGTTTCAGT
AAAAGTGCCTGATCCAAAATTCTCGAGCCAAACTAAAGATAAACTGGTTTCT
TCTGAAGTGAAATCAGCGGTTGAGTCGGCGATGGGTGAGAAGCTATCTGAGT
TCTTGGTCGAAAACCCAAGCGAAGCGAAGATGGTTTGTTCGAAAATCATCGA
TGCAGCACGTGCACGTGAAGCTGCACGTAAAGCGCGTGAAATGACTCGTCGT
AAAGGTGCGCTAGACCTAGCAGGCCTACCAGGC 
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Appendix B (Continued) 
recA alleles 
>recA-13 allele 
CGTGAAGGTAAAACTTGTGCGTTTATCGATGCTGAGCACGCGTTGGATCCTGT
GTACGCTAAAAAGCTTGGTGTTGATATTGATGCGCTATTGGTATCTCAGCCAG
ACACTGGTGAGCAAGCTCTAGAGATTTGTGATGCATTAGCTCGCTCTGGTGCA
ATCGACGTAATGGTTGTTGACTCTGTTGCTGCTCTAACACCTAAAGCTGAGAT
CGAAGGTGAAATGGGCGACAGCCACATGGGTCTCCAAGCTCGTATGCTTTCT
CAAGCAATGCGTAAGCTTACAGGTAACCTGAAACAGTCTAACTGTATGTGTA
TCTTCATCAACCAAATCCGTATGAAGATTGGTGTGATGTTCGGTAACCCTGAA
ACGACTACTGGCGGTAACGCGCTTAAGTTTTACGCTTCTGTTCGTTTAGATAT
CCGTCGTACTGGCGCAATCAAAGAAGGC 
 
>recA-14 allele 
CGTGAAGGTAAAACTTGTGCGTTTATCGATGCTGAGCACGCGTTGGATCCTGT
GTACGCTAAAAAGCTTGGTGTTGATATCGATGCACTATTGGTTTCTCAACCAG
ACACTGGTGAGCAAGCTCTAGAGATTTGTGATGCATTAGCTCGCTCTGGCGC
AATCGACGTAATGGTTGTTGACTCTGTTGCCGCTCTAACACCTAAAGCTGAGA
TCGAAGGCGAAATGGGTGATAGCCACATGGGTTTGCAAGCTCGTATGCTTTC
TCAAGCAATGCGTAAGCTTACAGGTAACCTGAAACAGTCTAACTGTATGTGT
ATCTTCATCAACCAAATCCGTATGAAGATTGGTGTGATGTTCGGTAACCCTGA
AACGACTACTGGCGGTAACGCGCTTAAGTTTTACGCTTCTGTTCGTTTAGATA
TCCGTCGTACTGGCGCAATCAAAGAAGGC 
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Appendix B (Continued) 
>recA-15 allele 
CGTGAAGGTAAAACTTGTGCGTTTATCGATGCAGAGCACGCTCTAGATCCTGT
ATATGCAAAGAAACTTGGCGTTGATATCGATGCACTATTGGTTTCTCAACCAG
ACACTGGTGAGCAAGCTCTAGAGATTTGTGATGCATTAGCTCGCTCTGGCGC
AATCGACGTAATGGTTGTTGACTCTGTTGCTGCTCTAACACCTAAAGCTGAGA
TCGAAGGCGAAATGGGCGACAGCCACATGGGTCTCCAAGCTCGTATGCTTTC
TCAAGCAATGCGTAAGCTTACAGGTAACCTGAAACAGTCTAACTGTATGTGT
ATCTTCATCAACCAAATCCGTATGAAGATTGGTGTGATGTTCGGTAACCCTGA
AACGACTACTGGCGGTAACGCGCTTAAGTTTTACGCTTCTGTTCGTTTAGATA
TCCGTCGTACTGGCGCAATCAAAGAAGGC 
 
>recA-16 allele 
CGTGAGGGTAAAACTTGTGCGTTTATCGATGCAGAGCACGCTCTAGATCCTGT
ATATGCAAAGAAACTTGGCGTTGATATCGATGCACTATTGGTTTCTCAACCAG
ACACTGGTGAGCAAGCTCTAGAGATTTGTGATGCATTAGCTCGCTCTGGCGC
AATCGACGTAATGGTTGTTGACTCTGTTGCTGCTCTAACACCTAAAGCTGAGA
TCGAAGGCGAAATGGGCGACAGCCACATGGGTCTCCAAGCTCGTATGCTTTC
TCAAGCAATGCGTAAGCTTACAGGTAACCTGAAACAGTCTAACTGTATGTGT
ATCTTCATCAACCAAATCCGTATGAAGATTGGTGTGATGTTCGGTAACCCTGA
AACGACTACTGGCGGTAACGCGCTTAAGTTTTACGCTTCTGTTCGTTTAGATA
TCCGTCGTACTGGCGCAATCAAAGAAGGC 
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Appendix B (Continued) 
>recA-17 allele 
CGTGAAGGTAAAACTTGTGCGTTTATCGATGCAGAGCACGCTCTAGATCCTGT
ATATGCAAAGAAACTTGGCGTTGATATCGATGCACTATTGGTTTCTCAACCAG
ATACTGGTGAGCAAGCTCTAGAGATTTGTGATGCATTAGCTCGCTCTGGCGCA
ATCGACGTAATGGTTGTTGACTCTGTTGCAGCTCTAACACCTAAAGCTGAGAT
CGAAGGTGAAATGGGCGACAGCCACATGGGTCTCCAAGCTCGTATGCTTTCT
CAAGCAATGCGTAAGCTTACAGGTAACCTGAAACAGTCTAACTGTATGTGTA
TCTTCATCAACCAAATCCGTATGAAGATTGGTGTGATGTTCGGTAACCCTGAA
ACGACTACTGGCGGTAACGCGCTTAAGTTTTACGCTTCTGTTCGTTTAGATAT
CCGTCGTACTGGCGCAATCAAAGAAGGC 
 
>recA-18 allele 
CGTGAAGGTAAAACTTGTGCGTTTATCGATGCTGAGCACGCTCTAGATCCTGT
ATATGCAAAGAAACTTGGCGTTGATATCGATGCACTATTGGTTTCTCAACCAG
ACACTGGTGAGCAAGCTCTAGAGATTTGTGATGCATTAGCTCGCTCTGGCGC
AATCGACGTAATGGTTGTTGACTCTGTTGCTGCTCTAACACCTAAAGCTGAGA
TCGAAGGTGAAATGGGCGACAGCCACATGGGTCTCCAAGCTCGTATGCTTTC
TCAAGCAATGCGTAAGCTTACAGGTAACCTGAAACAGTCTAACTGTATGTGT
ATCTTCATCAACCAAATCCGTATGAAGATTGGTGTGATGTTCGGTAACCCAGA
AACGACTACTGGCGGTAATGCGCTTAAGTTTTACGCTTCTGTTCGTTTAGATA
TCCGTCGTACTGGCGCAATCAAAGAAGGC 
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Appendix B (Continued) 
>recA-19 allele 
CGTGAAGGTAAAACTTGTGCGTTTATCGATGCAGAGCACGCTCTAGATCCTGT
ATATGCAAAGAAACTTGGCGTTGATATCGATGCACTATTGGTTTCTCAACCAG
ACACTGGTGAGCAAGCTCTAGAGATTTGTGATGCATTAGCTCGCTCTGGCGC
AATCGACGTAATGGTTGTCGACTCTGTTGCTGCTCTAACACCTAAAGCTGAGA
TAGAAGGCGAAATGGGCGACAGCCACATGGGTCTGCAAGCTCGTATGCTTTC
TCAAGCAATGCGTAAGCTTACAGGTAACCTGAAACAGTCTAACTGTATGTGT
ATCTTCATCAACCAAATCCGTATGAAGATTGGTGTGATGTTCGGTAACCCTGA
AACGACTACTGGCGGTAACGCGCTTAAGTTTTACGCTTCTGTTCGTCTAGATA
TCCGTCGTACTGGCGCAATCAAAGAAGGC 
 
>recA-20 allele 
CGTGAAGGTAAAACTTGTGCGTTTATCGATGCTGAGCACGCGTTGGATCCTGT
GTACGCTAAAAAGCTTGGTGTTGATATCGATGCGCTATTGGTATCTCAGCCAG
ACACTGGTGAGCAAGCTCTAGAGATTTGTGATGCATTAGCTCGCTCTGGCGCC
ATCGACGTAATGGTTGTTGACTCTGTTGCTGCTCTAACACCTAAAGCTGAGAT
CGAAGGTGAAATGGGCGACAGCCACATGGGTCTCCAAGCTCGTATGCTTTCT
CAAGCAATGCGTAAGCTTACAGGTAACCTGAAACAGTCTAACTGTATGTGTA
TCTTCATCAACCAAATCCGTATGAAGATTGGTGTGATGTTCGGTAACCCTGAA
ACGACTACTGGCGGTAACGCGCTTAAGTTTTACGCTTCTGTTCGTTTAGATAT
CCGTCGTACTGGCGCAATCAAAGAAGGC 
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>recA-21 allele 
CGTGAAGGTAAAACTTGTGCgTTTATcGATGcAGAGCACGCTCTAGATCCTGT
ATATGCAAAGAAACTTGGCGTTGATATCGATGCACTATTGGTTTCTCAACCAG
ACACTGGTGAGCAAGCTCTAGAGATTTGTGATGCATTAGCTCGCTCTGGCGC
AATCGACGTAATGGTTGTTGACTCTGTTGCTGCTCTAACACCTAAAGCTGAGA
TCGAAGGTGAAATGGGCGACAGCCACATGGGTCTACAAGCTCGTATGCTTTC
TCAAGCAATGCGTAAGCTTACAGGTAACCTGAAACAGTCTAACTGTATGTGT
ATCTTCATCAACCAAATCCGTATGAAGATTGGTGTGATGTTCGGTAACCCAGA
AACGACTACTGGCGGTAATGCGCTTAAGTTTTACGCTTCTGTTCGTTTAGATA
TCCGTCGTACTGGCGCAATCAAAGAAGGC 
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Appendix C.  Proteins expressed in one strain and not the other at 12°C 
Table A-2. Proteins expressed in one strain and not the other at 12°C 
Protein Name Non-pandemic Pandemic 
hypothetical protein Vex2w_02003774  + - 
putative secretion protein - + 
putative glycosyltransferase - + 
putative translation factor - + 
putative ABC transporter substrate-binding protein - + 
Chaperonin, 60 kDa subunit - + 
phosphoribosylamine-glycine ligase - + 
hypothetical protein VP1521 + - 
glucosamine-6-phosphate isomerase + - 
oxaloacetate decarboxylase, alpha subunit + - 
thiamin biosynthesis lipoprotein ApbE - + 
hypothetical protein VP2850 - + 
conserved hypothetical protein VP3051 - + 
prolyl endopeptidase + - 
putative V10 pilin - + 
conserved hypothetical protein VP1238 + - 
fumarate reductase, flavoprotein subunit + - 
autoinducer-2 production protein LuxS + - 
peptidase B + - 
prolyl endopeptidase - + 
hypothetical protein VPA0279 - + 
50S ribosomal protein L2  - + 
long-chain fatty acid transport protein - + 
riboflavin synthase, beta subunit - + 
protein-export membrane protein SecD - + 
1,4-alpha-glucan branching enzyme + - 
3,4-dihydroxy-2-butanone 4-phosphate synthase  + - 
putative lipoprotein - + 
putative exported protein - + 
hypothetical protein VP1085 - + 
protease HslVU, ATPase subunit HslU + - 
hypothetical protein VP1522 - + 
hypothetical protein VPA0868 - + 
BolA/YrbA family protein  + - 
inorganic pyrophosphatase + - 
cell division protein MukB - + 
Asparagine synthase (glutamine-hydrolyzing)  - + 
Chemotaxis protein CheW + - 
phosphoserine phosphatase + - 
putative long-chain-fatty-acid-CoA ligase - + 
1-deoxyxylulose-5-phosphate synthase + - 
deoxyribose-phosphate aldolase + - 
hypothetical protein VchoR_02002504  - + 
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putative SAM-dependent methyltransferase - + 
50S ribosomal protein L18 - + 
putative sensory box/GGDEF family protein  - + 
oligopeptidase A - + 
3-phosphoglycerate kinase  + - 
hypothetical protein Vex2w_02001021 + - 
RNA polymerase sigma factor RpoD + - 
fructose-bisphosphate aldolase  + - 
Transaldolase B + - 
co-chaperonin GroES + - 
outer membrane protein OmpW + - 
MukE protein + - 
fumarate and nitrate reduction regulatory protein + - 
ATPase component of ABC transporter with duplicated ATPase 
domains  
+ - 
glycyl-tRNA synthetase, alpha chain + - 
hypothetical protein VP2627 + - 
glucosamine--fructose-6-phosphate aminotransferase, isomerizing  + - 
2-dehydro-3-deoxyphosphooctonate aldolase + - 
Glucosamine 6-phosphate synthetase  + - 
conserved hypothetical protein VP0611 + - 
Chromosomal DNA replication initiator DnaA + - 
TolR membrane protein + - 
hydrogenase accessory protein HypB  + - 
hypothetical protein V12G01_03155  + - 
hypothetical protein V12G01_18112  + - 
N-acetylglucosamine-6-phosphate deacetylase + - 
Homocysteine synthase + - 
adenosine deaminase + - 
Sun protein + - 
succinylglutamate 5-semialdehyde dehydrogenase + - 
putative VgrG protein + - 
ibosomal lrg subunit pseudouridine synthase D + - 
MTA/SAH nucleosidase + - 
orotidine 5'-phosphate decarboxylase + - 
inosine-guanosine kinase + - 
hypothetical protein V12B01_21087  + - 
capsular polysaccharide transport protein + - 
AsmA protein + - 
hypothetical protein RRSL_03956  + - 
flagellar P-ring protein precursor  + - 
hypothetical protein VP0450 + - 
survival protein SurA + - 
hypothetical protein SKA34_04685  + - 
hypothetical protein VP0962 + - 
Na+/H+-exchanging protein + - 
histidinol phosphatase-related protein + - 
putative glycosyl transferase family protein + - 
GCN5-related N-acetyltransferase:CoA binding domain  + - 
excinuclease ABC, subunit A + - 
Protein of unknown function DUF160  + - 
Transcription-repair coupling factor (superfamily II helicase)  + - 
hypothetical protein lpp2873  + - 
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tryptophan synthase; beta subunit  + - 
thiol:disulfide interchange protein DsbE + - 
Ung + - 
hypothetical protein PdenDRAFT_3550  + - 
thermostable carboxypeptidase 1 + - 
asparagine synthetase B, glutamine-hydrolyzing - + 
Uroporphyrinogen decarboxylase HemE  - + 
diaminobutyrate-pyruvate aminotransferase - + 
integration host factor, alpha subunit - + 
serine transporter - + 
serine protein kinase - + 
hypothetical protein VP2178 - + 
amino acid ABC transporter, ATP-binding protein - + 
hypothetical protein VV11332  - + 
Hypoxanthine ribosyl transferase - + 
lysyl-tRNA synthetase-related protein - + 
Hemolysin - + 
serine peptidase DegQ  - + 
lipoprotein-related protein - + 
hypothetical protein VPA0928 - + 
chemotaxis methyltransferase CheR - + 
cytochrome c oxidase, subunit CcoO - + 
glutamate 5-kinase - + 
dihydroxy-acid dehydratase  - + 
probable transcription regulator protein  - + 
phenylalanyl-tRNA synthetase, alpha chain - + 
3-isopropylmalate dehydratase, small subunit - + 
peptidase, insulinase family - + 
RnfG-related protein - + 
Response regulator receiver:ATP-binding region, ATPase-
like:Histidine kinase A, N-terminal  
- + 
maltodextrin phosphorylase - + 
conserved hypothetical protein VP1129 - + 
peptidase T  - + 
polar flagellar protein FliL - + 
hypothetical protein VPA0178 - + 
putative rare lipoprotein A - + 
long-chain-fatty-acid-CoA ligase - + 
conserved hypothetical protein VP2997 - + 
phosphoribosylglycinamide formyltransferase - + 
fumarate reductase, 13 kDa hydrophobic protein - + 
conserved hypothetical protein  - + 
putative ubiquinone biosynthesis protein AarF - + 
Maltoporin precursor (Maltose-inducible porin) - + 
glycerol uptake facilitator protein GlpF - + 
D-glucose-1-phosphate thymidylyltransferase - + 
ribosomal protein L31 - + 
ATP synthase F1, delta subunit - + 
pyruvate-formate lyase-activating enzyme  - + 
shikimate 5-dehydrogenase  - + 
Transaldolase - + 
iron-sulfur cluster-binding protein  - + 
hypothetical protein RcanM_01000910  - + 
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putative ABC superfamily transport protein - + 
glycolate oxidase, subunit GlcD  - + 
hypothetical protein VP1269 - + 
ABC superfamily (glycine/betaine/proline transport protein) - + 
DnaK-related protein - + 
putative OtnG protein - + 
FeS assembly protein SufD  - + 
dihydroxy-acid dehydratase - + 
thymidylate kinase - + 
dihydroorotate dehydrogenase - + 
transcriptional regulator, GntR-family  - + 
beta-lactamase-like  - + 
hypothetical protein VPA1115 - + 
guanosine-5'-triphosphate,3'-diphosphate pyrophosphatase - + 
putative TEGT family carrier/transport protein - + 
hypothetical protein VP1594 - + 
signal peptidase I - + 
hypothetical protein VP2167 - + 
hypothetical protein VP1400 - + 
putative NDP-hexose 3-C-methyltransferase protein  - + 
3-hydroxybutyryl-CoA epimerase, delta(3)-cis-delta(2)-trans-
enoyl-CoA isomerase  
- + 
Aspartokinase I/homoserine dehydrogenase, threonine-sensitive + - 
phosphatidylserine decarboxylase - + 
hypothetical protein SproDRAFT_1096  - + 
hypothetical protein VP0219 - + 
ABC-type Fe3+ transport system, permease component  - + 
DNA topoisomerase IV - + 
molybdopterin biosynthesis MoeA protein  + - 
hypothetical protein PM1947  - + 
CreA protein - + 
hypothetical protein DP1223  - + 
amino acid ABC transporter, periplasmic amino acid-binding 
protein 
- + 
Electron transport complex, RnfABCDGE type, E subunit  - + 
hypothetical protein XautDRAFT_4167  - + 
DnaJ-related protein - + 
Signal transduction histidine kinase-like  + - 
conserved hypothetical protein, probable DNA/RNA helicase  - + 
putative lipoprotein  + - 
erythrose-4-phosphate dehydrogenase - + 
putative CMP-N-acetlyneuraminic acid synthetase - + 
hypothetical protein VP1084 - + 
hypothetical protein RSP_3467  - + 
chemotaxis protein CheA + - 
conserved hypothetical protein VP0956 - + 
pilin glycosylation protein - + 
outer membrane protein + - 
conserved hypothetical protein VP2762 - + 
lysine decarboxylase - + 
RpsL protein  - + 
pyruvate dehydrogenase, decarboxylase subunit, thiamin-binding 
protein  
+ - 
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FKBP-type peptidyl-prolyl cis-trans isomerase  + - 
RpoS + - 
putative SpoOM-related protein + - 
short-chain dehydrogenase/reductase SDR  + - 
ABC-type transport system, involved in lipoprotein release, 
permease component  
+ - 
type II/IV secretion system protein  + - 
NAD(P)H-flavin reductase + - 
3-dehydroquinate synthase  + - 
DNA-binding ATP-dependent protease La  - + 
Formate C-acetyltransferase  - + 
L-allo-threonine aldolase - + 
dethiobiotin synthetase - + 
hypothetical protein VP1131 - + 
hypothetical protein VP2588 - + 
hypothetical protein VP0698 - + 
non-ribosomal peptide synthetase  + - 
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Appendix D.  Expression of Cold Shock and Cold Acclimation Proteins at 12°C 
 
Table A-3. Expression of Cold Shock and Cold Acclimation Proteins at 12°C 
 Protein 
Peroxidase/catalase HPI 
CspB 
CspG 
InfA  
Polynucleotide phosphorylase (PNP) 
Desaturase, DesA & DesB 
γ-glutamyltranspeptidase 
DnaJ 
DesK 
DesR 
CshA 
CshB 
HtpG 
Not Present 
peptidylprolyl isomerase 1A 
Cold shock transcriptional regulator, CspA 
DNA gyrase alpha subunit 
Elongation factor Tu 
RecA 
NusA 
H-NS 
CsdA 
Trigger Factor, TF 
Hsc66 
RbfA 
InfB 
Pyruvate dehydrogenase, AceE 
Dihydrolipoamide acetyltransferase, AceF 
Both Strains 
DnaK 
DnaK-related Pandemic Strain 
DnaJ-like 
Non-Pandemic Strain DnaA 
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Appendix E. Proteins Identified in Gel Bands Associated with Protein Size 
 
Table A-4. Proteins Identified in Gel Bands Associated with Protein Size 
52 KDa Gel Band 
DnaA-1 JM109 
Chromosomal replication initiator protein dnaA Not Present 
Elongation factor Tu Present 
Enolase Present 
Outer membrane protein A precursor Present 
ATP synthase subunit beta Present 
Tryptophanase Present 
60 kDa chaperonin Present 
Aldehyde dehydrogenase A Present 
ATP synthase subunit alpha Present 
Trigger factor Present 
Glycerol kinase Present 
Glyceraldehyde-3-phosphate dehydrogenase A Present 
6-phosphogluconate dehydrogenase, decarboxylating Not Present 
Phosphoglycerate kinase Not Present 
Acriflavine resistance protein A precursor Not Present 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex 
Present 
Isocitrate dehydrogenase [NADP] Not Present 
Adenylosuccinate synthetase Not Present 
Dihydrolipoyl dehydrogenase Present 
Aminoglycoside 3'-phosphotransferase Not Present 
ATP-dependent hsl protease ATP-binding subunit hslU Present 
Aspartate ammonia-lyase Present 
Pyruvate kinase I Present 
Glutamate decarboxylase alpha Present 
Long-chain fatty acid transport protein precursor Present 
Pyruvate kinase II Present 
Serine hydroxymethyltransferase Not Present 
Transcription termination factor rho Not Present 
Aminoacyl-histidine dipeptidase Present 
Protease do precursor Not Present 
Xaa-Pro dipeptidase Present 
Chaperone protein dnaK Present 
Outer membrane protein tolC precursor Present 
Protein hflK Not Present 
Putative uroporphyrinogen-III C Present 
Signal recognition particle protein Not Present 
Biotin carboxylase Not Present 
Glutamyl-tRNA synthetase Not Present 
Xaa-Pro aminopeptidase Not Present 
Inosine-5'-monophosphate dehydrogenase Not Present 
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31 KDa Gel Band 
DnaJ-1 JM109 
DnaJ-releated protein Not present 
33 kDa chaperonin Not present 
6-phosphofructokinase isozyme 1 Not present 
60 kDa chaperone Not present 
adenylate kinase Present 
ADP-L-glycero-D-manno-heptose-6-epimerase Not Present 
aerobic respiration control protein Present 
Agmatinase Not Present 
alkyl hydroperoxide reductase subunit C Present 
Aminoglycoside 3'-phosphotransferase Present 
ATP synthase gamma chain Not Present 
catabolite gene activator Present 
chaperone protein DnaK Not Present 
chaperone protein htpG Not Present 
cystine-binding periplasmic protein Present 
D-methionine-binding lipoprotein Present 
D-ribose-binding periplasmic protein Present 
elongation factor P Present 
elongation factor Tu Present 
FKBP-type peptidyl prolyl cis-trans isomerase Present 
fumarate reductase iron-sulfur subunit Not Present 
glycerol kinase Present 
histidine-binding periplasmic protein Not Present 
methionine aminopeptidase Not Present 
Osmotically-inducible protein Y precursor Present 
oxidoreductase ucpA Not Present 
oxygen-insensitive NAD(P)H nitroreductase Present 
Peptidoglycan-associated lipoprotein precursor Present 
peptidyl-prolyl cis-trans isomerase B Present 
periplasmic oligopeptide-binding protein precursor Not Present 
proP effector Not Present 
purine nucleoside phosphorylase Present 
ribosome recycling factor Present 
septum site-determining protein MinD Present 
stringent starvation protein A Present 
succinate dehydrogenase iron-sulfur subunit Present 
superoxide dismutase (Mn) Not Present 
Transcriptional regulatory protein OmpR Present 
triosephosphate isomerase Present 
uracil phosphoribosyltransferase Present 
Uridine phosphorylase Present 
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